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There is a significant decrease in the productivity of the drug development 
pipeline due to low drug solubility and high toxicity. Promising solutions to these issues 
are to use solubilizing excipients and targeted drug delivery systems (DDS).  
There is a constant demand for an increased diversity of excipients and DDSs 
because no one host molecule can encapsulate all drugs. Here we study the use of three 
novel cucurbit[n]uril (CB[n])-type compounds synthesized by Dr. Lyle Isaacs. Motor1 
and Motor2 are highly soluble (105 mM and 14 mM) and unique in acyclic structure. The 
targeted delivery of drugs was explored using biotin functionalized CB[7].  
Phase solubility experiments evaluated improvements to drug solubility. Host 
biocompatibility was assessed both in vitro and in vivo.  In vitro bioactivity studies were 
conducted using Motor1 complexed with several anticancer drugs and biotin 
functionalized CB[7] complexed with oxaliplatin. Studies with Motor1 were repeated in 
vivo using NUDE mice baring human cervical cancer cell tumors.  
 
 
Motor1 and 2 significantly increased the solubility of drugs from many different 
therapeutic fields, such as paclitaxel (anticancer), cinnarizine (antihistamine), and 17a-
ethynyl estradiol (hormone). CB[7] and Motor1 were non-toxicity up to 10 mM in human 
liver and kidney cell lines. Female Swiss Webster mice continued to gain weight and 
appeared healthy after three intravenous doses of Motor1 up to 1230 mg/kg. Bioactivity 
assays using anticancer drugs paclitaxel albendazole, camptothecin and PBS-1086 
complexed in Motor1 resulted in significant cytotoxicity in HeLa cells. A pilot in vivo 
tumor treatment study showed tumor growth stabilization with these treatments. Biotin 
functionalized CB[7] showed cytotoxicity specifically in cells overexpressing the biotin 
receptor upon targeted delivery of oxaliplatin.  
The CB-type compounds significantly increased the solubility of a large variety of 
drugs across therapeutic fields. This coupled with host toxicity and drug bioactivity data 
indicate that these CB[n]-type compounds may be invaluable contributions to the toolbox 
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Chapter 1. INTRODUCTION 
1.1 The Drug Development Process  
For decades, new medicines have increased and improved the quality and extent 
of life for billions of people across the globe. Just over the past 10 years, the US has seen 
an almost 40% decrease in deaths due to cardiovascular disease, and significantly 
increased life expectancy for HIV and cancer patients as a result of novel therapeutic 
agents[1]. Therefore, the discovery and development of drugs is an integral part of public 
wellbeing. The quality and safety of these new therapeutic compounds has been of utmost 
importance since colonial times. Governmental regulation of drug development and 
marketing first started with the initiation of the Vaccine Act in 1813 followed by the 
evaluation of imported drugs and agricultural products in 1848[2]. The Food and Drug 
Administration (FDA), the oldest consumer protection agency, founded in 1906, passed 
the Pure Food and Drugs Act in 1906 outlawing commercial companies from 
“adulterating and misbranding” food and drugs. However, there had not been any 
regulations requiring drugs and foods be tested prior to marketing[3] until 1938. In 1937, 
an untested compound called Elixir Sulfanilamide killed over 100 people, many of whom 
were children. Public outrage pushed the government to step in and pass the Food, Drug 
and Cosmetic (FDC) Act that ensured any future drugs be proven safe before being 
marketed[2]. This was later enforced in 1962 by the Kefauver-Harris Drug Amendments 
which detailed the importance of proving efficacy and greater drug safety. Finally, in 
1949, the FDA published the first set of guidelines concerning the production and 
processing of foods and drugs[2].  
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The FDA has evolved since these early years and is now heavily involved in the 
assessment of both domestic and imported foods and drugs in order to ensure adequate 
efficacy and safety. The FDA plays an integral part in each stage of the drug development 
process. This process begins after the discovery of lead compounds and consists of 
preclinical testing, clinical trials and finally approval and marketing by the FDA. Each of 
these steps is governed by specific guidelines that must be fulfilled before approval can 
be granted[4] (Figure 1). There are three primary categories that are tested for during 
preclinical and clinical trials. Researchers and industry promoting new drug candidates 
must firmly establish the compound’s adequate efficacy, pharmacology and reasonable 
safety [4-7]. Efficacy addresses the question of whether a compound can elicit the 
proposed and necessary response needed for treatment of the specific disease. 
Pharmacology essentially defines what happens to a compound once it is administered 
(pharmacokinetics) and also what happens to the organism in response to the test 
compound (pharmacodynamics). During preclinical and clinical assessment of a 
candidate compound, it must be established that its benefits significantly outweigh its 











Figure 1: The drug development pipeline in the United States. The drug development 
process in the U.S involves preclinical testing of candidate drugs using cell based assays 
and both rodent and non-rodent animal models. This is followed by FDA monitored 
clinical trials in humans, approval/disqualification, and marketing. Each stage of the 
pipeline is designed to evaluate three main drug properties: safety, efficacy and 
pharmacokinetics/dynamics. Figure by Gaya Hettiarachchi 
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Preclinical testing of drugs involves extensive in vitro and in vivo analysis of test 
compounds to firmly determine these three properties. After rigorous testing, in both cell 
based assays and rodent and non-rodent animal models, an Investigational New Drug 
(IND) can be filed to receive approval for clinical trials[4]. An IND includes the 
submission of preclinical data on animal toxicology, efficacy, and pharmacology, 
manufacturing details including the full chemical composition and formulation of the 
compound and detailed clinical protocols to minimize unnecessary risk to humans. Once 
the FDA has reviewed the IND to ensure that adequate safety, efficacy and 
pharmacokinetics has been established and that clinical trials can be conducted safely, the 
second stage of the approval process can begin[4, 5]. 
 Clinical trials involve the use of human volunteers to assess the safety, efficacy 
and pharmacokinetics to determine optimum dosage for a test compound. These trials are 
often conducted by a medical professional and the length of the trials depends on the 
specific drug. There are three different clinical trials that must be conducted, Phase I-III, 
during an approval process[4]. During Phase I, drug testing is conducted at a small scale, 
between 20-100 volunteers. This is the stage at which toxicity, metabolism and excretion 
are evaluated.  If the candidate compound tests well, it moves into Phase II which 
comprises of a larger group of volunteers, usually ranging between 100-500 volunteers. 
During Phase II, efficacy is evaluated along with further studies into compound safety. 
Finally, Phase III includes the largest scale analysis in clinical trials involving 
approximately 1000-5000 volunteers. Further evaluation of efficacy and toxicity is 
conducted at this time and dosage is determined[4]. All clinical trials must be conducted 
5 
 
under good clinical practice (GCPs) guidelines which includes human subject protection 
(HSP) to ensure the safety of volunteers during these trials[4].  
 Once the necessary clinical trials are completed, a New Drug Application (NDA) 
is filed with the FDA clearly stating the findings of all preclinical and clinical trials 
including compound formulation, dosage regime, and proposed labeling. This 
information allows for the FDA committee to assess whether the compound is safe and 
effective in its proposed use, whether the benefits of the drug significantly outweighs its 
risks, if the labeling is appropriate and complete, and, finally, whether the manufacturing 
process allows for the maintenance of the compound’s quality including strength and 
purity. The NDA, if approved, allows for marketing and sales of the proposed 
compound[4]. 
 
1.1.1 Drug Development Attrition  
Even though the quality of public health relies heavily on the development and 
commercialization of investigational molecules through the above mentioned process, it 
is concerning to see that the productivity of the drug development pipeline has 
significantly decreased[4, 8-10]. For every 10,000 candidate compounds entering the 
developmental pipeline, only about 250 pass through preclinical trials[10]. Once a 
compound reaches Phase I clinical trials, it’s estimated to have only an 8% chance of 
being marketed [11, 12]. In clinical trials, attrition rates are upwards of 37% in Phase I, 
62% in Phase II and 45% in Phase III[11]. In addition to this, approximately $800 million 
to $2 billion and over 10 years are invested in developing just one new drug from 
discovery to marketing [4, 9, 12]. Therefore, this decline in developmental productivity 
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leads to a significant waste of financial and material resources and also limits the 
diversity of effective drugs in the market. This decrease in productivity is referred to as 
drug development attrition[4, 12, 13]. In 2004, the FDA released a statement addressing 
this issue and, in 2006, they published the Critical Path Initiative (CPI) to help industry 
battle increasing costs and developmental attrition [11, 14] The CPI addressed several 
reasons for increasing attritions rates but emphasized the need for new scientific tools to 
improve compound formulation and testing to study and enhance drug properties. 
Though establishing drug safety, high efficacy and pharmacokinetics is 
increasingly essential during the developmental process, these three properties are also 
the largest contributors to developmental attrition[4]. High toxicity, seen as adverse 
effects, in humans, is responsible for about 11% of failing drugs while the lack of 
efficacy contributes to about 30% of all drugs failing the developmental pipeline[15, 16] 
(Figure 2). Finally, the most significant factor affecting a candidate compound’s success 
is its bioavailability. Low drug bioavailability contributes to at least 39% of all lead 
compounds failing the developmental pipeline[15].  
Developmental attrition is observed across therapeutic fields, but is more 
prominent and detrimental in specific diseases such as cancer. Cancer is a disease of the 
cells that is the leading cause of mortality contributing to about 13% of all deaths 
worldwide in 2008. Lung, stomach, liver, colon and breast cancers have been shown to 
have the highest rates of mortality[17]. This high rate of mortality can, in large part, be 
attributed to the lack of effective drugs. Studies have shown that the success rate for 
candidate anti-cancer drugs within the drug development pipeline is only about 5%[12]. 
It should be noted that even marketed anticancer drugs have limited use. This attrition is 
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 Once potential drug bioactivity is established at the discovery stage, the first and 
foremost study that is conducted is a comprehensive analysis of the compound’s 
toxicity[19, 20]. Toxicity is evaluated at several stages of the drug development 
pipeline[5, 21]. There are several different forms of toxicity, each of which, if severe 
enough, can lead to the elimination of a drug from the development pipeline. As stated 
before, it is essential that the benefits of a test compound greatly out way its risks in order 
to obtain FDA approval[21].  Oxaliplatin is an example of an anticancer drug that is dose 
limited by its high toxicity. This drug works by binding to DNA, in turn, forming adducts 
that prevent DNA synthesis thus inducing cell death. Oxaliplatin is a very potent 
compound that is effective against a large variety of different types of cancer, however, it 
is limited by its severe peripheral neuropathy and neurotoxicity[22, 23]. Despite these 
adverse effects, oxaliplatin is still used at lowered doses in the combination with other 
anticancer drugs to enhance efficacy[23, 24]. 
 Because the key to alleviating attrition due to toxicity is its efficient prediction 
before the drug candidate reaches later stages of development, understanding the different 
forms of toxicity and using the appropriate assays to detect it is essential[19, 25]. The 
FDA has set guidelines for industry and investigators to help in the proper evaluation of 
drug toxicity[26]. They recommend testing and providing adequate information on single 
and multiple dose toxicity that may stem from immunological, biologically activated, 
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genetic, reproductive and/or developmental toxicities [5, 25-27]. In vivo toxicity can be 
presented as a maximum tolerated dose (MTD), or lethal dose (LD50)[20]. 
 
Immunological Toxicity 
 There are five different forms of immunological toxicity; however, the most 
common are hypersensitivity and immunogenicity to test compounds or their metabolites 
[26-28]. Drug compounds can bind to and react with proteins that induce the production 
of antibodies, release cytokines, or induce inflammation[28]. One example is the 
hypersensitivity to cremophor®EL observed in many patients who are administered this 
solvent in complex with an insoluble drug [29-31]. Cremophor®EL is a surfactant that 
was used to solubilize compounds such as the anti-cancer drug paclitaxel (Taxol®). Even 
though this combination was used for years to treat many types of cancer, the 
hypersensitivity to cremophor®EL has been shown to include clinical outcomes such as 
respiratory arrest, cardiac collapse and, in some cases, death [29, 30]. Approximately 
41% of all patients receiving Taxol® produced symptoms of severe hypersensitivity. 
How these adverse reactions are brought about is still unclear, but complement activation 
by cremophor®EL is thought to be responsible[31].  
Immunological toxicity can sometimes be difficult to predict early on in 
development as a result of individual vulnerabilities in the immune system. However, 
several assays like ELISAs can be used to detect cytokine release or antibody production. 
These assays can be run using serum collected from humans and animals following 
dosing of the test compound. Collected blood samples can also be used to establish white 




Biologically Activated Toxicity 
 Toxicity resulting from bioactivation is primarily due to the production of toxic 
by-products during drug metabolism. The liver is the principle organ responsible for drug 
modification. Metabolism can produce either deactivated, ineffective or potentially toxic 
metabolites that lead to liver, blood or other organ toxicity. This problem can be 
somewhat addressed by dose control or medicinal chemistry approaches to substitute 
sensitive functional groups [32, 33]. One such example is Acetomenaphine, the most 
widely used drug in the United States. Acetomenaphine has a well-established record of 
safety and efficacy, however, overdose of this drug can lead to severe liver damage and 
even liver failure due to the accumulation of the toxic metabolite, NAPQI (N-acetyl-p-
benzoquinone imine), in the liver[34, 35].   
Biologically activated toxicity in the liver can be predicted through extensive 
preclinical assays using liver derived microsomes and several isolated CYP450 enzymes. 
These tools can be used to metabolize drug candidates and check for improper 




 Genetic toxicity is defined by the ability of a compound to damage the DNA 
and/or chromosomes of cells. This damage can then lead to genetic mutations that can, in 
turn, lead to certain diseases such as cancer or birth defects defined as 
carcinogenicity[39]. There are several examples of drugs and substances that have been 
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earmarked to be genetically toxic or carcinogenic. Many anticancer drugs, like tamoxifen 
and melphalan, are categorized as “Known to be a human carcinogen” by the National 
Toxicology Program (NIH)’s Twelfth Edition (2011) Report on Carcinogens[40]. 
Furthermore, cyclosporine A, an immunosuppressant used in organ transplants, is also 
categorized as “Known to be a human carcinogen.”[40] 
FDA guidelines require the assessment of both in multiple ways. Some in vitro 
mammalian cell assays include the mammalian lymphoma assay and the Ames test [41-
43]. However, following these cell based evaluations, long-term mutogenecity and 
carcinogenicity studies in animal models must also be conducted to adequately determine 
the presence or absence of this form of drug toxicity [27, 39, 42, 44, 45].  
 
 Reproductive and Developmental Toxicities 
Reproductive toxicities refer to damage inflicted on organism fertility, parturition 
and lactation while developmental toxicity refers to damage to embryo survival, growth, 
or malformations [27, 46, 47]. One example of a drug that has been shown to cause 
reproductive toxicity in animals and humans is the broad spectrum antibiotic tetracycline 
[48].  
Reproductive toxicity can be evaluated with histopathological studies conducted 
using an animal model following repeated dosing of the test compound. Furthermore, 
these dosed mice can be mated to not only further evaluate the effects of the candidate 
compound on reproductive organs but also on the development of an embryo and fetus 
[46, 47, 49]. Damage to embryos with the use of a candidate drug can be assess through 
the frog embryo teratogenesis assay, for example, which is essentially a 96-hour whole 
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embryo assay that can measure a compound’s ability to induce mortality, malformation, 
and growth inhibition. Long- term, multiple doses studies may need to be conducted in 
the in vivo preclinical and clinical stages to further assess these types of toxicities [46, 47, 
49, 50].  
 
1.1.1.2 Efficacy 
Drug efficacy, another factor contributing to the developmental success of a 
candidate drug, is defined as the maximum response a compound has in its proposed use 
[4, 19, 51, 52]. Efficacy depends on drug composition or chemistry and testing for it will 
depend on the drug’s purpose or activity[16]. Efficacy has to be established both in vitro 
and in vivo in preclinical testing as well as in clinical trials and is usually presented as the 
effective or inhibitory concentration (EC50 or IC50) at which a response halfway between 
the baseline and maximum responses is observed [19, 51, 52]. These values are 
calculated from a dose-response curve [4, 16, 52]. 
Factors leading to developmental attrition.   
Low drug efficacy is a growing problem in current day drug development, 
resulting in approximately 30% of all failed compounds in the FDA approval process and 
countless more during drug discovery and preclinical trials [5, 12, 15]. Many of these 
abandoned compounds are shelved while resources are funneled into the synthesis of new 
candidate drugs. There are several factors that can cause low drug efficacy. One example 
may be that the drug does not bind to the appropriate receptors. Another is that even if it 




Low drug efficacy is a fast growing problem. Many of these drugs go through 
preclinical and clinical trials and are shown to be safe for human use, but are not used for 
actual treatment of diseases due to low efficacy in their proposed purpose[54]. To address 
this, the FDA and the NIH have turned their attention to repositioning and repurposing 
many of these abandoned drugs[55]. This idea essentially proposes to take these 
abandoned, yet safe drugs and find uses for them in the treatment of other common or 
rare diseases. This concept has been around for some time now, for example zidovudine 
(better known as AZT), a nucleoside analog reverse-transcriptase inhibitor, was originally 
developed to treat cancer but was abandoned due to low efficacy. However, this drug was 
re-investigated during the HIV/AIDs epidemic and became the first drug to be used to 
treat patients with HIV/AIDs[54].  There are many other drugs like zidovudine that have 
been repurposed in the past, however, as a result of a significant increase in 
developmental attrition in recent years, several organizations like the FDA and the NIH, 
came together to form specialized programs solely for this purpose. One such program is 
the National Center for Advancing Translational Sciences (NCATS) branch of the 
NIH[56]. This program has invited researchers to find new uses for 58 compounds 
released by 8 pharmaceutical companies. All 58 drugs were evaluated through preclinical 
testing and their safety was established in human clinical trials but were abandoned due 
to low efficacy in their initially proposed uses[57] Another program set forth by the FDA 
(Office of Orphan Products Development)  focuses on the repurposing of both marketed 
and abandoned drugs for the treatment of rare diseases; from this program the Rare 





Drug pharmacokinetics include several components: absorption (A) of a 
compound across mucosal surfaces such as the epithelial layer of the GI tract, the 
systemic distribution (D), liver metabolism (M) and finally the excretion (E) of the 
compound from the system[15, 59, 60]. The ADME is also referred to as a compound’s 
bioavailability or the rate and extent to which it reaches its necessary site of activity [7, 
15, 61, 62]. One of the most significant factors contributing to bioavailability is its 
aqueous solubility as will be discussed in further detail later [60, 63, 64]. Low 
bioavailability has become such a predominant problem in drug development that it is 
specifically addressed in the CPI set forth by the FDA to improve attrition rates. The CPI 
proposes researchers and industry test their novel compounds is a Phase 0 or eIND stage 
prior to filing an IND for Phase I clinical trials[11]. These Phase 0 trials would involve 
using nontherapeutic, microdoses of drug to help weed out compounds with suboptimal 
pharmacokinetics.  During these trials, doses less than 1/100
th
 of the therapeutic range 
would be administered to human volunteers, and extremely sensitive analytical tools 
would be used to detect pictogram levels of the drug and metabolite concentrations. This 
testing phase can give a “go/no go” for further clinical study of the candidate compound. 
However, there are several disadvantages to using this testing step. One such major issue 
is that at such low doses, many insoluble drugs will readily dissolve and exhibit 
properties of good absorption. However, when therapeutic doses are used, the low 
solubility of the drug becomes a major limiting factor[11].  
In vivo, drug bioavailability can be measured by administering the candidate drug 
orally, through a gavage for example, and then collecting blood samples at various time 
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points. These values can then be plotted as a concentration vs. time curve. The area under 
the curve (AUC) of this graph is referred to as a drug’s overall bioavailability [7, 59, 60, 
65]. This value is usually expressed as percent bioavailability of oral administration 
compared to the i.v administration of the same dose. This method is applied to iv 
administered drugs as well[66]. Other important factors of bioavailability that should be 
calculated from these experiments are a drug’s volume of distribution (Vd)[67], 
excretion[68] half-life and clearance[69] rate.    
 
Absorption 
The absorption of a drug refers to the movement of the compound across mucosal 
surfaces into the bloodstream. This phenomenon is usually used to define what happens 
to a drug candidate after oral administration [59, 70, 71]. Orally administered drugs move 
into the small intestine where they have to be absorbed through the epithelial layer of the 
GI tract. Absorption is important for the delivery of drugs to therapy targets that are in 
tissue other than the stomach and GI tract and can only successfully be reached through 
the blood circulation system. Therefore, after oral administration, inadequate drug 
absorption can lead to insufficient concentrations of the drug reaching the blood stream 
for systemic distribution. This directly leads to low bioavailability. Compound absorption 
across mucosal surfaces can be measured using in vitro assays such as the concentration 
gradient across a monolayer of human epithelial (Caco-2) cell line[72]. In vivo, 
compounds can be fed to animals through an oral gavage and concentrations of the 
candidate drug can be measured in the blood over the course of time. 
Factors leading to developmental attrition. 
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Drug solubility, dissolution, permeability, the presence or absence of food in the 
stomach, pH, chemical reactions in the GI tract and the presence of enzymes and bacteria 
all influence drug absorption [62, 66, 71].  
The solubility, dissolution and permeability of drug candidates allows for the 
organization of drugs into the Biopharmaceutics Classification System (BCS) [60, 70]. 
The BCS categorizes orally administered drugs into four classes (I-IV). A compound’s 
absorption and classification depends on three molecular properties: solubility, 
permeability and dissolution [60, 70]. Permeability is defined as a compound’s ability to 
cross mucosal barriers. For classification purposes, a compound is considered highly 
permeable if its absorption is 90% or more of the administered dose in comparison to an 
intravenous dose (100%) of the same drug. Dissolution is defined as the rate at which a 
compound goes into solution. A high dissolution rate is defined by whether 85% of the 
therapeutic dose dissolves in a volume less than 900 ml within 30 minutes[70]. 
Compounds with lower dissolution rates have a lower rate of absorption which can 
sometimes be advantageous towards prolonged efficacy of potent drugs. However, this 
can also be a limiting factor for drugs with lower efficacy that need to reach the necessary 
site of activity at high concentrations. Finally, a compound is considered highly soluble if 
the highest dose strength can be solubilized in 250 ml or less aqueous solution over a pH 
range of 1-7 [70]. Drug solubility and dissolution can be tested for in vitro by using 
solutions that mimic stomach and gastric fluid[72]. Furthermore, permeability can be 
assessed in vitro by measuring drug transport across a monolayer of the human epithelial 
cell line, Caco-2[72]. 
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Class I orally administered compounds are both highly soluble and highly 
permeable; these compounds are readily absorbed and the rate of absorption is usually 
higher than the rate of elimination[70]. Class I drugs can be formulated into a simple 
solid oral dose. One example of a class I drug is metoprolol which is a β1 receptor blocker 
commonly used to treat heart disease and hypertension[70]. Class II compounds have 
high permeability and low solubility; the rate of absorption of these compounds is limited 
by how quickly they are solubilized, or their rate of dissolution. These compounds 
generally require a solvent or surfactant to improve solubility. An example of a class II 
drug is naproxen which is a non-steroidal anti-inflammatory drug (NSAID)[70]. Class III 
molecules have low permeability and high solubility; these drugs have high dissolution 
rates, however, the drug’s bioavailability is limited by its absorption rate. These 
compounds require permeability enhancers and/or highly localized concentrations in the 
lumen of the GI tract. One example of a class III drug is cimetidine which inhibits 
stomach acid production and treats acid reflux binding to histamine H2-receptor[70]. 
Finally, Class IV compounds have low permeability and low solubility and thus overall 
low bioavailability. These compounds require solubilizing agent, permeability enhancer 
and high localized concentrations of the drug at the site of absorption.  An example of a 




During systemic distribution the drug will pass in and out of different organs and 
allow for it to reach its necessary site of activity. Some factors that influence the adequate 
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systemic distribution and survival of a drug and, thus its bioavailability, are drug 
solubility, size, and composition[67]. Drug distribution can be measured by excising 
organs and collecting blood from a treated animal, such as a mouse, and determining the 
concentration of drug in each organ and blood [7, 67].  
Factors leading to developmental attrition. 
During a drug’s systemic distribution, its solubility, size, and composition will 
either facilitate or inhibit the uptake and retention of the compound in tissue and organs. 
Furthermore, drugs can face degradation or inactivation through blood enzymes[67]. 
Most drugs are in equilibrium between drug molecules that are unbound and bound to 
blood proteins. This balance depends on the molecular properties of the drug and also 
dictates how much and how quickly the free drug can reach its necessary site of activity 
[67, 73]. Drugs also run the risk of being phagocytized and degraded by blood cells such 
as macrophages that decreases drug bioavailability. Finally, after tissue penetration, it 
may be necessary for the drug to cross cell membranes in order to reach intracellular sites 
of activity which provides yet another obstacle against drug bioavailability. Finally, 
molecular properties can also dictate which tissue or organs these compounds accumulate 
in. Many compounds tend to accumulate in the liver or kidneys. One example is cisplatin 
which is a potent anticancer drug that favorably accumulates in the kidney, leading to 
severe hepatic toxicities[74].  
 
Metabolism 
Drug metabolism is the process by which compounds are prepared for excretion. 
Metabolism primarily occurs in the liver and is usually conducted through the system of 
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CYP450 enzymes. There are two forms of drug metabolism in the body, first-pass and 
second-pass metabolism. First-pass metabolism occurs in the liver and is responsible for 
the majority of drug metabolism[75]. As stated before, microsomes extracted from 
human livers or purified CYP450 enzymes can be used, in vitro, to predict the extent of 
metabolism a candidate drug will go through[7]. 
Factors leading to developmental attrition. 
Metabolism is a major contributing factor influencing bioavailability because the 
rate and extent to which the drug is metabolized, plus the metabolites formed, affect the 
quantity and amount of time the active drug circulates in the blood system[32]. A second 
consequence of drug metabolism is the formation of harmful metabolites that can result 
in liver damage and other adverse effects in vivo as discussed before[75]. However, some 
investigators have used metabolism to their advantage when formulating a compound by 
using a prodrug system[76]. When the prodrug passes through the liver, the metabolism 
of the compound produces an active form of the drug. This byproduct can then enter 
systemic distribution as an active compound. 
After orally administered compounds are absorbed through the GI tract, they are 
directed into the liver through the hepatic portal vein for modification in preparation for 
excretion. Liver metabolism can break down a candidate drug into inactive components 
or toxic metabolites in preparation for excretion. The polarity of the compound influences 
the extent to which it will be degraded in the liver[32]. If a compound is polar and soluble 
enough in aqueous solution, it can be eliminated from the body with minimal 
modifications through the urine. However, if a compound is non-polar it will need to be 
modified by the CYP450 in order to prepare the compounds for coupling with a 
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solubilizing agent[32]. Drug compounds must survive unmodified through the liver’s 
metabolic system in order to reach the blood full efficacy intact. Extensive metabolism 
leads to low drug bioavailability[75]. 
With i.v administered drugs, metabolism can occur as a result of enzymes and 




 Finally, the drug will be cleared from the blood by kidney filtration and excreted 
through the urine. Drugs passing through the kidneys undergo glomerular filtration, 
active tubular secretion and passive tubular reabsorption. Glomerular filtration is the first 
step of renal excretion and is the process during which free drug enters the renal tubule. 
Filtration occurs in the glomerulus of the kidney[77]. If a drug is highly bound to plasma 
proteins, this will be a slow process. Another process drugs undergo is active tubular 
secretion which happens in the proximal tubule of the kidney. Weak acids and bases 
usually undergo active tubular secretion. Drugs may also be passively reabsorbed in the 
blood stream from the tubular lumen. The extent of reabsorption depends on the drugs 
lipophilic properties, urine pH, and chelating agents[77].  
Excretion and clearance rate are usually determined by quantifying the amount of 
drug present in urine and bile over a period of time[7]. It can also be determined by 





Factors leading to developmental attrition. 
Excretion becomes a contributing factor towards low drug bioavailability when 
the candidate compound is eliminated from the body too quickly through the liver or 
kidney filtration, thus, reducing the amount of time it has to circulate the blood system 
and limiting its access to the target site[77]. Furthermore, inadequate or inefficient 
excretion can lead to high drug concentrations that can result in toxicity. 
 
1.1.2 Summary  
The drug developmental pipeline is essential for the wellbeing of public. This 
pipeline encompasses all stages after the discovery of a drug candidate and involves 
preclinical and clinical trials with final FDA approval and marketing. Preclinical and 
clinical trials focus on three main properties of a candidate drug: its toxicity, efficacy and 
pharmacology.  
 A few essential types of toxicity that should be tested for prior to FDA approval 
are immunotoxicity, hypersensitivity, genetic toxicity and reproductive and 
developmental toxicity[25]. In vivo toxicity can be presented as an MTD value or LD50 
value. Key organs that should be assessed are the liver and kidneys as these are organs 
where drugs are metabolized and tend to have extended periods of higher concentrations 
of the drugs. Drug efficacy should be evaluated in vitro and in vivo using dose response 
experiments and is typically presented as an EC50 or IC50 value. Finally, the 
pharmacology of a candidate drug is of utmost importance [51, 52]. Research should be 
conducted using rodent and non-rodent model to determine the bioavailability of the 
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candidate. Metabolic rate and characteristics of any metabolites should also be recorded 
along with the clearance rate[69], and distribution properties[67]. 
 The compilation of all this data in the preclinical setting allows for the 
successfully filing of an IND and helps predict the drug’s success in clinical trials, and 
also helps determine protocols and dosing for clinical trials[26]. Addressing these topics 
in human trials allows for the adjustment of doses and the assessment of the overall 
feasibility of marketing the drug. 
Even though the drug development pipeline from preclinical through clinical 
evaluation of a candidate’s toxicity, efficacy, and pharmacology is essential to public 
wellbeing, the productivity of this pipeline has significantly decreased (citation). 
Toxicity, efficacy and pharmacology evaluation along the way can uncover many 
suboptimal properties of a candidate drug which can lead to its elimination from the drug 
development pipeline. This will result in a significant waste of time and resources and 
ultimately lead to decreased diversity of drugs in the market. Two of the highest 
contributing factors that can lead to drug developmental attrition are low bioavailability 
as a result of low drug solubility[78] and dose limiting toxicity[25]. 
 
1.2 Solubilizing Excipients and Drug Delivery Systems  
For many years, researchers and industry have struggled to find an adequate 
solution to growing drug development attrition. Solubilizing agents and, in recent years, 
drug delivery systems (DDS) have emerged and continue to grow exponentially as a 
promising solution [79-81]. Solubilizing excipients can aid in the development and 
approval of drugs because they can enhance the solubility of drugs, thereby, allowing for 
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the formulation of therapeutically efficacious doses. In addition to increasing drug 
solubility, DDSs have the unique ability to enhance stability, reduce the toxicity, and 
improve the pharmacological properties of problem drugs [60, 78]. Additionally, DDSs 
have the unique abilities to allow for controlled release and target the delivery of 
drugs[82]. This is especially important in cancer treatment where the majority of anti-
cancer drugs are toxic to healthy tissue resulting in severe adverse side effects[83]. 
Tumor specific properties like the over-expression of folate and biotin receptors can be 
used to target drugs to these cancerous cells specifically by using folate[84] or biotin[85] 
functionalized drug delivery molecules. Furthermore, DDSs could allow for the co-
delivery of two or more drugs allowing for efficient combination therapy [81, 86].  
Drug delivery systems have also opened the door to the evolution of novel 
therapies that exclude chemical molecules such as siRNA for cancer treatment[87]. 
Without drug delivery systems, siRNA was subject to fast degradation in human serum, 
limited distribution and cellular uptake. Furthermore, free siRNA was known to cause 
severe immune responses, off-target toxicity effects, depletion of certain blood cells and 
organ toxicity in liver, spleen, and kidney. As a result, in vivo, siRNA proved very 
difficult to use until DDSs were used to appease these harsh side effects and improve 
stability and uptake [83, 87].  
Due to these numerous advantages, it can be thought that by coupling problem 
drugs to DDSs or solubilizing excipients, thus improving their bioavailability, toxicity 
and/or efficacy, these new formulations can re-enter the FDA approval process and 
successfully be marketed [88]. This would, in turn, reduce attrition rates, costs and waste 
of valuable resources and increase the diversity and availability of therapeutic 
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compounds to the public[89]. In fact, the CPI set forth by the FDA suggests doing just 
this by emphasizing the development of new technologies, like nanotechnology, to 
address increasing attritions rates[11].  
It is essential that an efficient excipient or DDS be highly soluble in aqueous 
solution, highly biocompatible and be eliminated from the body efficiently so as to not 
cause toxic accumulation[90]. The binding affinity between the excipient or DDS and the 
drug must be strong enough to allow for binding and retention of the guest but also weak 
enough to allow for the unloading of the drug when required. This release of the drug 
may be triggered by different stimuli including pH, and competitive displacement 
compounds that offset the equilibrium between bound and unbound guest molecules[90]. 
They should also have a certain amount of selectivity towards specific drugs. This would 
naturally entail that no one DDS will be able to bind to and improve the molecular 
properties of all drugs, thus, there is a need for a large diversity of DDSs[89, 90]. 
There are many different kinds of excipients and DDSs currently being studied, 
some of which are approved by the FDA and marketed across therapeutic fields [89, 90]. 
Below is a summary of some of the most widely studied. Furthermore, a new family of 
macromolecules, the cucurbit[n]urils (CB[n]), will be discussed.  
 
1.2.1 Polymer-Based Drug Delivery Systems 
Polyethylene Glycol (PEG) 
A polymer is a compound that is comprised of repeating structural units. Specific 
kinds of polymers, particularly ones that are water-soluble and generally inert, can be 
utilized for drug delivery purposes. Polymer therapeutics includes polymer-drug 
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conjugates, polymer-protein conjugates, and polymeric nanoparticles[91]. Conjugation of 
polymers to drugs or other carrier molecules can serve as drug delivery resulting in 
enhanced drug solubility, increased systemic circulation, protection from enzymes, 
reduced immunogenicity, passive targeting of drugs to tumors and controlled release of 
drugs based on the structural specificity of the polymer chains that dictate their 
degradation[92]. There are many different kinds of polymeric units that can be used as 
drug delivery systems, one of the most commonly used is polyethylene glycol (PEG). 
Consisting of repeating ethylene oxide subunits, the unique properties of these polymers 
rely on the length of their chains. PEG is water soluble, and FDA approved and currently 
used in a large variety of foods, cosmetics and pharmaceuticals[92].  
Currently there are PEGs ranging from 300-10,000,000 g/mol available 
commercially. Ideally, chain lengths of upwards of 2000 g/mol leads to increased 
solubility, in vivo stability and systemic circulation [91, 93, 94]. As a drug delivery 
system, PEG can be bound to hydrophobic or hydrophilic compounds in order to 
solubilize and prolong the systemic circulation of drugs. These polymers accomplish this 
by protecting drug compounds from being cleared through the reticuloendothelial system 
(RES), which can severely limit the systemic circulation of a drug. The RES is a 
clearance system that is part of the immune system and is comprised of phagocytic cells, 
primarily monocytes and macrophages, that localize in the lymph nodes and spleen[91]. 
PEG chains limit the uptake of drug compounds by phagocytic cells like macrophages in 
the blood and also slow the degradation of drug compounds by enzymes by preventing 
their binding. This, in turn, increases the systemic circulation of drug compounds, 
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allowing for higher drug concentrations in the blood and more time for these drugs to 
reach their necessary site of activity[91].  
PEGylated compounds can also passively target pharmaceutical agents to tumors 
during cancer treatment. This is called the enhanced permeability and retention (EPR) 
effect [95-97]. When tumors develop, rapidly growing cells are in need of large quantities 
of nutrients and oxygen quickly. As a result, tumor vasculature develops rapidly and, in 
turn, abnormally. The EPR effect takes advantage of this irregular tumor vasculature[97]. 
The phenomenon states that compounds of certain size and chemical properties can 
favorably accumulate in tumors as opposed to healthy tissue because they can enter and 
accumulate in the tumor vasculature [96, 98, 99]. This entrapment allows for drugs to be 
retained in the tumor for extended periods of time at higher concentrations. This is a 
method that is currently being studied as a drug targeting mechanism to alleviate high 
toxicity[100]. Furthermore, increased circulation time and selective distribution of PEG-
drug particles may allow for improved drug pharmacokinetics and, in turn, bioavailability 
[98, 100]. 
There are, however, several disadvantages to the use of PEG chains as DDSs. 
Specific chains of PEG have been shown to be somewhat difficult to formulate and 
purify, and, therefore, can be fairly expensive to use. Furthermore, these polymer arms 
have been found to be difficult to conjugate to drugs without changing drug bioactivity, 
and are not compatible with all compounds[92]. Therefore, PEG is primarily used as 
attachments to nanoparticles like liposomes for drug delivery. Secondly, though the 
longer the chain length of these polymers, the better the solubility and circulation time, 
extensive polymerization can lead to self-association and nanoparticle aggregation 
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leading to inefficient drug loading[100]. Finally, recent studies have shown that repeat 
dosing of PEGylated compounds can elicit an immune response through complement 
activation, hence, leading to hypersensitivity [101, 102]. PEG, also does not degrade 
readily, which enhances the systemic circulation of a drug, but can also decrease the 
activity of said drug because of the lack of release of the drug [100]. When PEG does 
degrade, it is broken down into ethylene glycol units which are categorized as “Known to 
be a human carcinogen”[40]. PEG and the EPR effect will be further discussed in Project 
2 section. 
PEG is used in several marketed laxatives such as MiraLAX®. Another example 
of a PEGylated compound is Genexol-PM® [103] which is currently in clinical trials. 
Genexol-PM® is a PEGylated micelle formulation of the anticancer drug PTX.  
 
1.2.2 Lipid-Based Drug Delivery Systems 
Liposomes 
Liposomes were first discovered in 1961 by Alec D. Bangham and were initially 
used to study cell membranes before its utility as a DDS was discovered. Nearly 2,000 
papers and more than a 150 reviews were published in 2003 alone on the subject of 
liposomology[104]. These nanoparticles are composed of a lipid or phospholipid bilayer 
membrane surrounding an aqueous center (Figure 2). There are two types of liposomes: 
multilamellar, which are vesicles formed of multiple bilayers, and unilamellar, which are 
containers composed of only one lipid bilayer. Small unilamellar vesicles are usually 
within the size range of 100 nm while large unilamellar vesicles are in the range of 200-
800 nm. Multilamellar vesicles are within the size range of 500-5000 nm[104]. 
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Liposomes have the ability to delivery both hydrophilic and lipid soluble drugs and have 
the unique ability to fuse to cellular lipid membranes and degrade into highly 
biocompatible components. These nanoparticles can be formulated into different forms of 
administration such as oral or intravenous. Another advantage to the liposomes is that the 
phospholipid bilayer of liposomes can be easily modified to customize the molecules to 
varying sizes. They have also been shown to induce the EPR effect at specific sizes. 
Liposomes can also protect their cargo from degradation [104, 105]. 
Liposomes have several disadvantages that limit their use[106]. One of the 
primary downfalls of the liposome is its rapid clearance from the body through the RES. 
The high clearance rate of liposomes has been somewhat circumvented with the use of 
PEG arms bound to the surfaces of liposomes, in turn, protecting the liposomes from 
phagocytosis and protein degradation [105, 107]. These new long-circulating liposomes 
are now marketed as STEALTH® liposomes [88, 107, 108]. However, these new 
liposomes have their own limitations, such as the difficulty with which the vehicles are 
modified with PEG arms and the fact that it can limit the adhesion of targeting ligands. 
These PEG molecules have also shown higher levels of hypersensitive reactions as 
explained before. In addition, while the protection of liposomes from the RES clearance 
system improves circulation time, this lack of uptake up by cells is observed in tumor 











Figure 2: Liposomes are composed of a lipid or phospholipid bilayer membrane 
surrounding an aqueous center. Hydrophilic compounds can be loaded in its aqueous 
cavity while hydrophobic compounds with high binding affinities can be loaded into the 








Methods to circumvent this problem involve using stimuli induced disconnection of PEG 
chains from liposomes. One such trigger would be the lower pH observed in tumor tissue. 
Liposomes have also been known to have high production costs, low solubility, leakage 
of encapsulated drugs and possibly elicit an immune reaction [107, 110, 111]. Another 
limitation of the liposome is its drug encapsulation efficiency. This is a problem primarily 
with hydrophobic drugs like paclitaxel (PTX) which have very low affinity to the lipid 
bilayers of liposomes. Liposomes can only be used to delivery drugs that can be 
efficiently encapsulated within the nanoparticle with strong binding affinities so as to 
limit the amount of lipid being administered. Administering high concentrations of lipids 
can lead to  toxicity and unpredictable pharmacokinetics[112].   
Liposomes have been coupled with a large variety of drugs, primarily anticancer 
compounds, some of which are currently approved and marketed. One such approved 
complex is the drug now marketed as Doxil® [88, 113]. This formulation is composed of 
the anticancer drug doxorubicin encapsulated in STEALTH® liposomes[108]. 
Encapsulation with PEGylated liposomes have both enhanced the solubility and reduced 
the side effects of this drug. This complex is currently being used to treat ovarian cancer. 
Liposomes have also served as carriers for other insulin[114], cytokines like recombinant 
TNF-α[115], antimicrobial agents[116], and siRNA[117]. In addition to parenteral 
delivery, liposomes can be used for oral delivery as demonstrated by preliminary studies 
conducted with insulin[114]. They can also be used for aerosolized delivery as shown by 
the delivery of rifampicin to alveolar macrophages, showing promise in enhanced 
Tuberculosis treatment[116]. Liposomes can also be targeted using different ligands such 
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as folate[118, 119], and transferrin[120] whose receptors are overexpressed on tumor 
cells and monoclonal antibodies[121].  
 
1.2.3 Macromolecular Excipients 
Cyclodextrins (CDs) 
Cyclodextrins (CDs) are one of the most extensively studied and widely utilized 
solubilizing excipients. The earliest reference to these molecules was in 1891 and by 
1953, the first patent for drug formulations emerged[122]. CDs are cyclic 
oligosaccharides composed of 6-8 dextrose units joined through 1-4 bonds. There are 
three naturally occurring CDs: α, β and γ (Figure 3). The essential difference between 
each is the number of glucose subunits that composes each [123, 124]. These glucose 
subunits come together to form a hollow conical structure that allows for the 
encapsulation of different drugs in their cavities. CDs have hydrophilic exteriors and 
hydrophobic interiors that allow for the encapsulation of neutral or anionic guest 
molecules [122, 125]. The varying number of glucose subunits allows for different sized 
cavities; α-CD is a hexamer with a cavity diameter of 4.7-5.3Â; β-CD is a heptamer with 
a cavity size of 6.0-6.5Â and finally the γ-CD is composed of eight glucose subunits and 
has a cavity size range of 7.5-8.3Â (Figure 4). One of the greatest advantages of the CD 
family is their high solubility: 16 mM (β-CD), 149 mM (α-CD) and 178 mM (γ-CD). The 
loading of a drug into the cavity of a CD molecule is determined through many different 
factors. One obvious factor is whether regions of a particular drug can physically fit in 
the CD cavity. Structural and molecular properties, such as charge and hydrophobic and 
ionic regions, of the drug are also important[125]. CDs are more prone to bind to neutral 
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CD structure and solubility allows for these vehicles to encapsulate and hide 
hydrophobic drugs or hydrophobic regions of drugs from water molecules, thus allowing 
for the CDs to increase the solubilities of these compounds [125]. It should be noted, 
however, that solubilizing excipients like the CDs may not increase the solubility of the 
free drug, but will, instead, maintain the drug in aqueous solution by establishing a rapid 
equilibrium between the highly soluble complex (drug + CD) and poorly soluble free 
drug. Therefore, the total amount of drug present in solution, hence its solubility, refers to 


















Figure 3: The CD family: α-CD, β-CD, and γ-CD. α-CD is a hexamer with a cavity 
diameter of 4.7-5.3Â; β-CD is a heptamer with a cavity size of 6.0-6.5Â and finally the γ-
















It may be necessary for a drug to cross cellular and mucosal membranes in order 
to reach its necessary site of activity as stated earlier in this thesis. However, it is also 
accepted that CDs do not diffuse through cell or mucosal membranes. As a result, in 
order for the increase in drug solubility to lead to an increase in bioavailability and 
efficacy, it is obvious that the drug must be released from the CDs. The constant forming 
and breaking of bonds between CDs and drugs dictates that the drug can be released from 
the CDs and remain free when this equilibrium is changed. One factor that influences the 
equilibrium between bound and unbound drug is the binding affinity of the CD to the 
drug. If the binding affinity is high, then the CD and drug will be bound together tightly 
and result in decreased concentrations of free drug and thus decreased bioavailability. 
Another factor influencing the equilibrium is the ratio of CD:drug. This means that if 
there is a significantly higher concentration of CD than is needed to solubilize a specific 
amount of drug (an excess of CDs), there will be a decreased concentration of free drug 
at any given time. Therefore, during the process of drug formulation with excipients like 
the CDs, it is essential to consider drug binding affinities and appropriate CD:drug ratios 
in order to optimize the adequate release of the drug so that it may reach its necessary site 
of activity. Other possible factors that can influence the equilibrium and promote the 
release of the drug from the CDs are: 1) drug-protein binding that can cause a decrease in 
free drug concentration thereby shifting the equilibrium to release more drug from the 
CDs, 2) competitive displacement by an endogenous or exogenous compound that has 
higher affinity to the CD that can essentially kick the drug out and finally 3) drug uptake 
into tissue that are not accessible or conducive to complex or free CD uptake[125]. 
Furthermore, it is thought that, in the case of orally administered drugs, the empty CDs 
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can bind to and extract lipids from intestinal cell membranes thus changing membrane 
fluidics and membrane transport of free drug into the cells. This is thought to contribute 
to increased absorption of the drug across the mucosal surface and into systemic 
circulation.  
 Until recently, CDs have been tested primarily for oral administration of insoluble 
drugs[127]. The parent CD compounds have not been approved for use with i.v 
administered drugs in the US because of the severe nephrotoxicity observed with all three 
CDs [128, 129]. This toxicity primarily arises from the high affinity the CDs have for 
cholesterol and phospholipids[128]. When administered parenterally, CDs have been 
shown to extract erythrocytes and other blood cells of cholesterol leading to cell lysis and 
toxicity. This extraction of cholesterol not only leads to blood cell lysis but also has been 
shown to form crystals in the kidney and lead to severe renal toxicity[128]. Furthermore, 
studies have shown that this toxicity is not isolated to blood cells; CDs can extract 
phospholipids and proteins from other types of cells leading to cell death. The LD50 for 
i.v administration in rats has been established at 1g/kg for α-CD and 0.79 g/kg for β-
CD[129]. An LD50 of 3.75g/kg has been established in rats for γ-CD, however, some 
reversibility of this toxicity was also observed [128, 129].  
As a result of these limitations in i.v administration, several different CD 
derivatives have been synthesized; the two most well-known are hydroxypropyl-β-CDs 
(HP-β-CD)[130] and sulfobutyl ether-β-CD ((SBE)-β-CD)[131] now known as 
Captisol®. HP-β-CD has been shown to improve drug solubility, stability and overall 
bioavailability of guest compounds[132]. This derivative has a significantly improved 
safety profile than that of β-CD, however, this improvement comes at a cost; with the 
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higher degree of hydorxypropyl substitution, the CD’s ability to bind to drugs is 
decreased[133].  Parenteral administration of HP-β-CD has been tested in both animals 
and humans. Minor reversible histological changes in the kidney were observed at doses 
ranging from 100-400 mg/kg in addition to some damage to red blood cells. However, 
these effects were not readily reflected in humans[130]. Two year toxicology studies in 
humans did not show signs of carcinogenicity. HP-β-CD has also been used to orally 
delivery drugs, however, like the parent compounds, very limited amounts of CD reach 
the blood stream[134]. It is believed that the drug is released in the GI tract and it is then 
absorbed across the mucosal membrane without the CDs[130]. One approved and 
marketed drug that is formulated in HP-β-CD is itraconazole (antifungal)[135]. 
Furthermore, this CD derivative is currently in clinical trials for the treatment of 
Neimann-Pick Type C Disease which, without treatment, is a terminal disease affecting 
children by inhibiting the body’s ability to process cholesterol. Thus HP-β-CD has been 
pioneered to harvest excess cholesterol, in turn, improving patient survival[136]. 
(SBE)-β-CD or Captisol® is a very successful CD derivative that has shown high 
solubility and no interactions with cell membrane cholesterol or phospholipids. Parental 
studies done in mice up to 10 g/kg have shown no signs of toxicity. Similarly, human 
studies have shown no adverse effects. There are several Captisol® formulated drugs that 
are currently FDA approved and marketed including Nexterone (life threatening heart 
rhythm disorders), VFend® (antifungal), Geodon™(antipsychotic), Cerenia™ (motion 






The cucurbit[n]uril (CB[n]) family of macromolecules was first isolated by 
Behrend et al in 1905 through the condensation reaction of glycoluril and formaldehyde 
under acidic conditions[137]. These particles were fully characterized later by Mock et al 
in 1981. CBs are composed of repeating glycolurils that form a cylindrical structure much 
like the CD family[138]. The parent compounds of the CB[n] family include five 
compounds, CB[5], [6], [7], [8], and [10],  that vary in cavity size based on the number of 
glycoluril units each consists of (Figure 4). The CB[n] exteriors are hydrophilic and 
negatively charged at the portals and the interior cavity is predominantly 
hydrophobic[138]. Like the CDs, molecular properties of the guest, like charge and size, 
determine binding to CB[n] molecules[137]. Because of the negatively charged glycoluril 
groups at the portals of these containers and the hydrophobic interior, they favor the 
binding of positively charged particles with regions of hydrophobicity [139]. This family 
of nanoparticles is unique in their high binding affinity and specificity towards guest 
molecules. Because CB[n]s attract cationic and neutral molecules, they serve as a 
counterpart to the CD family that binds neutral or anionic guest molecules[138, 139]. It 




) to its guest 




) allowing for longer host-guest 
complexation, stabilization, and the need for significantly lower concentrations of 
excipient to solubilize equal amounts of drug[138]. For example, it was shown that >6 
times higher concentrations of β-CD than CB[7] is need to solubilize the same amount of 





Figure 4: The Cucurbit[n]uril Family: CB[5], CB[6], CB[7], CB[8] and CB[10]. Cavity 
sizes range from 4.4 Â(CB[5]), 5.8 Â(CB[6]), 7.3 Â(CB[7]), 8.8 Â (CB[8]), and 10.7-
















Aside from these advantages, there are several other properties that suggest the 
CB[n] family would be good solubilizing excipients. CB[5] and [7] are the most soluble 
of the family at 20-30 mM which is comparable to β-CD (16 mM) Though the parent 
CB[n] compounds are not as soluble as the parent CD compounds, CB[n]s have relatively 
weak basic portals which are protonated under acidic conditions, thus increasing the 
compounds' relative solubilities under acidic conditions such as that found in the stomach 
and small intestine[138, 139]. Even with somewhat limited solubility, members of this 
family have shown promising results in increasing the solubility and stability (both 
chemical and enzymatic) of certain drugs[143, 144]. Like with the CD family, it is 
thought that there is an equilibrium between CB[n] bound and unbound drug and, as a 
result the drug release mechanisms are thought to be similar.  
The CB[n] family (4.4-12.6 Â)  exceeds CDs (4.7-8.3 Â) in the range of cavity 
sizes which allows for larger drugs to bind to CB[n]s. CB[n] toxicity has been tested both 
in vitro and in vivo with promising results. In vitro testing in Chinese Hamster Ovary 
(CHO-K1) cells, human kidney (HepG2), and human kidney (HEK293) cell lines showed 
high cell survival up to 1 mM of CB[7] up to 48 hrs[141, 145]. An in vivo study using a 
single i.v dose of CB[7] up to 300 mg/kg established the MTD of CB[7] at 250 mg/kg. 
Mice recovered in weight within 5-8 days possibly suggesting reversible toxicity [141]. 
Uptake of CB[7] through phagocytosis has been demonstrated through fluorescence 
microscopy.  
Consequently, several studies have been conducted using CB[n]s in the past with 
oxaliplatin (anticancer)[141, 146], ABZ (anthelminthic/anticancer)[142], camptothecin 
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(CPT; anticancer)[147], cisplatin (anticancer)[148], and several anesthetics (procaine, 
tetracaine dibucaine etc.)[149]. However, none of these compounds have advanced to 
clinical trials or marketing yet. These studies do show great potential towards the use of 
CB[n]s for solubilizing and stabilizing purposes and, in fact, they seem to be great 
counterparts to the CD family of macromolecules.  
There are several factors that may limit the use of CB[n]s. One is the rigid circular 
structure of these compounds. Though their cavity sizes are larger than the CD family, 
their structure still limits the size of drug that can be bound to the CB[n]s. However, the 
most significant factor that may limit their use is their low solubility. CB[5] and CB[7] 
are the most soluble, however, CB[5] has been shown to be too small to encapsulate 
many drugs. CB[7] is, as a result, the most studied, but at a solubility of only 20-30 mM, 
the enhancement of drug solubility with this compound is limited[139].  
 
1.3 Summary and Significance 
Drug delivery systems provide many advantages in the pharmaceutical industry 
by being able to significantly increasing drug solubility, stability, enhancing systemic 
circulation, decreasing toxicity and providing the option to target drug to specific cells. 
Furthermore, solubilizing excipients like the CDs can significantly improve the solubility 
of many drugs. These advantages allow for problem drugs to be pushed through both the 
developmental and approval processes thus reducing attrition rates. There are many 
different kinds of excipients and DDSs currently being studied, the most prominent of 
which are PEG chains, liposomes and CDs. A fairly new family of macromolecules 
currently being studied for solubilizing purposes is the cucurbit[n]urils.  
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This dissertation work evaluates three new CB[n]-type molecular compounds, 
Motor1, Motor2 and a biotin functionalized-CB[7], developed during a five-year 
collaboration with Dr. Lyle Isaacs (University of Maryland, Department of 
Chemistry)[145, 150, 151]. With so many different types of successful excipients and 
DDSs being studied, one might ask why this work is significant. The answer lies in the 
fact that no one host molecule can bind to, solubilize and deliver all drug molecules. 
Therefore, a diversity of host molecules is necessary to encapsulate the large variety of 
problem drugs. It is essential to continually expand the tool box of drug delivery systems. 
Table 1 presents some compelling data collected by the Isaacs lab that strongly supports 
the need for a larger variety of excipients and delivery molecules and that these novel 










Table 1: Comparative study of drug solubilities with Motor1, Motor2 and HP-β-CD 
clearly revealed the need for a large toolbox of excipients and DDSs to accommodate the 
large diversity of drugs available. Many drugs like PBS-1086 and PTX show significant 
solubility enhancement with only Motor1, whereas CPT and estradiol showed the greatest 
increase in solubility with Motor2. The drugs presented here showed limited increases in 











The following information will be presented as two main projects. One will focus 
on using Motor1 and 2 to increase the solublities of several insoluble drugs. There are 
several advantages to Motor1 and 2 that support their use in this field. Not only do they 
have very high intrinsic solubilities (105 mM and 14 mM respectively) but they also have 
great structural flexibility due to their acyclic formation allowing for the encapsulation of 
larger variety of different sized drugs.  
The second section of this thesis will focus on alleviating drug toxicity by using 
ligand targeted CB[n] and CB[n]-type compounds. Targeted drug delivery can be used to 
alleviate anticancer drug toxicity by delivering these toxic drugs specifically to tumors by 
way of passive targeting or tumor specific ligands[90]. This will result in tumor specific 
cytotoxicity, leaving healthy cells unharmed and leading to decreased drug side effects. 
Here we will introduce a biotin targeted CB[7] compound that was tested for tumor 
specificity[151].   
Dr. Isaacs’ lab has evaluated the molecular properties of these three CB[n]-type 
including their intrinsic solubilities and drug solubilizing capabilities. My work has 
evaluated the biological significance of these increased solubilities and targeted drug 
























Project 1: Enhancing Drug Solubility using Novel CB[n]-
























Chapter 2. PROJECT 1 INTRODUCTION  
 
2.1 Drug Solubility 
Solubility is defined as the maximum amount of solute (eg: NaCL) that can 
dissolve in a given amount of solvent (eg: water) thus reaching a state of equilibrium 
between dissolution and precipitation of the solute[63].  A compound is soluble in a 
solvent when there are attractive molecular forces between the solute and solvent 
molecules making the reaction energetically favorable. For example, when NaCl 
dissolves in water, the positive Na
+
 ions are attracted to the somewhat negatively charged 
oxygens in H2O, while the negatively charge Cl
-
 ions are attracted to the positively 
charged hydrogen atoms of water. Furthermore, the polarity of the solute and solvent also 
determines solubility, if a compound is highly polar (hydrophilic) it will most like 
dissolve readily in water which is also polar. However a non-polar (lipophilic) compound 
(eg: oil) will not dissolve in a polar substance like water due to forces like the 
hydrophobic effect. Solubility is usually defined at standard temperature (25
0
C) and pH 
(7). Changing these parameters will increase or decrease the solubility of a compound. 
Solubility is expressed as a concentration (Molarity, g/L, etc) and usually refers to 
aqueous solubility unless specifically stated. The FDA defines a compound as highly 
soluble if the highest therapeutic dose necessary is soluble in 250 mL or less of aqueous 
solution over a pH range of 1-7.   
Low drug solubility is the major cause of drugs failing within the developmental 
pipeline due to low bioavailability[60, 64]. Approximately 70% of all orally administered 
drugs entering the pipeline have high permeability but are solely limited by their 
solubilities (Class II) (Figure 10)[1]. This fraction of the population is higher than that of 
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drugs in the pipeline limited solely by low permeability (Class III; <10%) or by low 
solubility plus low permeability (Class IV; 20%). This majority is reflected in marketed 
drugs with 30% of these drugs being limited solely by their solubilities[1]. Orally 
administered drugs are not the only compounds that suffer from low drug solubility. In 
fact, studies have shown that over 40% of all drug candidates, through all forms of 
administration, are failing the developmental process due to low solubility[60, 64, 78]. 
Low drug solubility directly affects the absorption of a drug across mucosal membranes 
in the orally administered compounds. It will lead to low or variable absorption of the 
compound into the blood stream, thus resulting in a limited amount of drug reaching 
systemic distribution. The end product of low drug solubility is low unpredictable 
bioavailability[64]. The solubility of a compound is also a fundamental factor in its 
formulation at clinically relevant dosages for i.v administration[60]. All of these factors 
can lead to the elimination and abandonment of the candidate drug during the 
developmental process thus leading to increased attrition rates[60, 64, 78].  
There are several different approaches to overcome low drug solubility[78]. 
Medicinal chemistry can help restructure candidate compounds early in the discovery and 
preclinical stages of development. However, in some cases, structural adjustments are not 
an option because it can compromise the potency of the drug. Therefore, other 
approaches to increase drug solubility are necessary. There are many different ways to 
improve the solubility of a drug. Some of these include adjusting pH, using salt solutions, 
or solid dispersions. Other methods include using excipients such as surfactants like 
cremophor®EL and CDs or DDSs like liposomes as mentioned before[60, 78]. Despite 
this large diversity of solubilizing strategies, each method has its advantages and 
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disadvantages that actually promote the need for such a large spectrum of methods.  
However, as stated before, no one host molecule can bind to and solubilize all drugs 
(Table1). As a result, there is a constant demand for a larger diversity of solubilizing 
agents. Therefore, here, we introduce two new CB[n]-type molecular compounds to add 
to the toolbox of solubilizing strategies [150]. This study will provide a proof-of-
principle for the use of Motor1 and 2 for drug delivery using four different anticancer 
drugs: PBS-1086, PTX, CPT and ABZ.  
 
2.3 Drugs with Low Solubility 
PBS-1086 
PBS-1086 is an un-marketed anticancer drug still in the preliminary 
developmental stages[152]. The mechanism of action for this compound is through the 
inhibition of both canonical and non-canonical NFκB pathways[152]. Both or one of 
these pathways is upregulated and constantly turned “on” in many types of cancer[153]. 
This is because the NFκB pathways are responsible for initiating DNA transcription, cell 
proliferation and survival which are favored in cancer growth and progression. PBS-1086 
is coined as a pan-Rel inhibitor because it can block the activity of all five members of 
the NFκB family of proteins that have the Rel homology domains responsible for DNA 
binding and dimerization. Blocking all five proteins down-stream of both pathways 
essentially inhibits the translocation of these proteins into the nucleus and, thus, the 
binding and initiation of DNA transcription[152]. PBS-1086 has shown promising results 
in the treatment of aggressive, usually terminal cancers such as head and neck cancers, 
however, it is severely limited by its very low, undetectable, solubility. Various studies 
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were conducted with other excipients without success, therefore, initial studies with this 
new compound were conducted using a mixture of DMSO and cremophor®EL. 
However, due to the toxicity issues associated with these solvents, an alternative was 
needed[152]. As a result, through a recent collaboration with relMD Inc. (Balitmore, 
MD) and Profectus Biosciences Inc. (Baltimore, MD) we were able to encapsulate the 
drug in Motor1 to significantly increase its solubility safely and thereby improve its 
therapeutic index. The fact that Motor1 can safely and significantly increase the solubility 
of PBS-1086 when other excipients could not is of great importance because it is an ideal 
example of how necessary it is to have Motor1 as an approved excipient. This is because 
drugs, like PBS-1086, that are affective against aggressive cancers, like head and neck 
cancers, are rare and, therefore, essential to public health. Without Motor1, further study 
and the possibility of approval or marketing of PBS-1086 may be limited.  
 
Paclitaxel (PTX) 
As previously discussed, PTX is a well-known, currently marketed anticancer 
drug that stabilizes microtubules essentially halting cellular replication[154]. This drug 
had been administered i.v using cremophor®EL, until recently, due to its very low 
solubility (0.03 mg/ml). Marketed under the name Taxol®, this formulation was used to 
treat a variety of different cancers, however, the severe side effects associated with this 
formulation was a dose limiting factor. Extensive research revealed that the majority of 
adverse effects observed with Taxol® administration was, in fact, due to cremophor®EL 
and not PTX[31]. Cremophor®EL causes severe hypersensitivity, nephrotoxicity, and 
neurotoxicity[29, 30]. As a result of these severe side effects, Taxol® was typically 
administered at a concentration of 175 mg/m
2
 over a period of 3 hrs[155]. Furthermore, 
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special packaging was necessary for storage and administration because cremophor®EL 
was found to leach plastic into the drug solution[31]. As a result of these limitations, a 
replacement for cremophor®EL is actively sought after, especially because this solvent is 
not only used in the administration of anticancer drugs, but also for the administration of 
drugs like cyclosporine A and several anesthetics. In fact, patients who have received 
liver transplants using cremophor®EL have exhibited cardiac toxicity. Therefore, 
replacing this solvent with an improved alternative would impact the administration of 
drugs across therapeutic fields[31].  
A new albumin formulation of this PTX, Abraxane®, is currently approved 
(2005) and marketed[156]. Clinical studies conducted with a dosing every 3 weeks using 
Abraxane® showed that with the elimination of cremophor®EL, PTX could be 
administered at an increased dose (260 mg/m
2
) over a shorter time period (30 mins) with 
decreased side effects in comparison to a dosing of 175 mg/m
2
 of Taxol® over 3hrs [156-
158]. However, this new formulation still has its own drawbacks such as, neutropenia 
(abnormally low number of neutrophils), sensory neuropathy (loose of sensation), 
alopecia (baldness), and hypersensitivity[156]. Furthermore, both reproductive and 
developmental toxicities were observed in rats.  This formulation also comes with the 
remote risk of transmitting viral diseases due to the human albumin used to solubilize 
PTX[156]. Though it is a significant improvement from Taxol®, it is clear that there still 
are limitations to this new formulation of PTX and plenty of room for improvement. As a 
result, there is still a great deal of interest in PTX. For example, Genexol-PM®, a 
PEGylated micelle formulation of PTX, is currently in clinical trials[103]. This 
formulation is thought to not only increase drug solubility but also improve PTX 
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pharmacokinetics by inducing the EPR effect. In our study, PTX will serve as a tool for 
establishing a proof-of-principle towards the use of novel CB[n]-type compounds for 
drug delivery.  
 
Camptothecin (CPT) 
CPT is an anticancer drug that works by blocking topoisomerase I, effectively 
halting DNA synthesis[159]. Though CPT has been shown to have good activity at lower 
concentrations, formulating this compound to doses with clinical efficacy has been 
difficult due to its low solubility (4 µg/ml)[160]. This low solubility has led to unreliable 
treatment and unpredictable adverse effects in humans. Furthermore, CPT is also limited 
by is in vivo instability. This compound is quickly hydrolyzed into an inactive, yet more 
soluble compound that has prolonged circulation time[160, 161]. As a result of these 
limitations, CPT research was abandoned early on and two new analogs, topotecan and 
irinotecan, were synthesized and marketed. Though these two new compounds have 
potent activity and good solubility, they also have dose-limiting toxicity which limits 
their clinical use. Several recent studies have tried to pull CPT back into clinical use, one 
such compound is currently in clinical trials. CRLX101 is a nanoparticle that is composed 
of CD and PEG repeating units that can bind to, solubilize and stabilize CPT[162, 163]. 
CPT is conjugated to the PEG units, thus preventing the hydrolysis of the drug and 
increasing its solubility by 3 orders of magnitude. This compound was also shown to 
increase drug circulation in vivo as a result of the PEG arms[163]. This compound has 
been moved into Phase II clinical trials. CPT has been successfully coupled with CB[7] 
and CB[8] with improved drug solubility and stability, therefore, CPT will serve as 




ABZ, the final drug that will be used in conjugation with Motor1, is a safe and 
approved orally administered anthelmintic drug that has been used for close to 30 years 
now. ABZ’s mechanism of action is very similar to that of PTX[164]. It can bind to and 
inhibit microtubule depolymerization leading to cell death. This drug was also shown to 
be a potent inhibitor of vascular endothelial growth factor (VEGF) which is upregulated 
in many tumors[165]. Due to these mechanisms of action, researchers recently became 
interested in the application of this drug in cancer treatment. A pilot study to determine 
MTD value was conducted in patients with colorectal and other forms of cancer. This 
study showed some decline in tumor biomarker levels in plasma with oral administration 
of ABZ[166]. The optimal dose was determined to be 1200 mg, twice daily on a 21-day 
cycle. Furthermore, rats with peritoneal human HT-29 tumors dosed i.p with ABZ at 150 
mg/kg on a once weekly schedule showed significant reduction of tumor volume. Finally, 
ABZ has been demonstrated to have potent activity against PTX resistant cells [164]. 
However, this drug has limited use due to its low solubility and rapid metabolism; it 
cannot be formulated at clinically relevant doses for i.v administration[165]. Due to the 
great potential ABZ has an anticancer drug in addition to its already well-established 
safety profile, many researchers have sought to improve its solubility by using DDSs. 
One such study used HP-β-CD which showed the ability to increase ABZ solubility up to 
1.2 mg/ml using 400 mM HP-β-CD[140]. Though this study showed promising results, 
one must remember the negative side effects associated with this derivative of the CD 
family. Furthermore, it has been shown that the CB[n] can bind to and solubilize ABZ 
more efficiently than the CD family with a lower concentration of the DDS. CB[6,7,8] 
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has been shown to increase the solubility of ABZ by 2000-fold without the addition of 
other solvents[142]. Therefore, here we will discuss the use of Motor1 conjugated ABZ 
in the treatment of tumors.  
 
2.4 Motor1 and 2 
Below we will discuss the conjugation of these four drugs and others with Motor1 
and 2 and present both chemical (Isaacs) and biological (Hettiarachchi) assessment of 
these compounds. Both these compounds are acyclic and, as a result, are extremely 
flexible in binding to various sized guest molecules. It is composed of the same essential 
backbone as the parent CB[n] compounds and has negatively charged exteriors and a 
hydrophobic interior[150, 167], therefore, it has high affinity to both  neutral and 
positively charged guest molecules with hydrophobic regions. The positive charges on 
the guest can induce ion-dipole interactions with the negatively charged portals on 
Motor1 and hydrophobic interactions are formed between the cavities of both compounds 
with respective regions on guests. Furthermore, the two terminal aromatic groups on both 
Motor1 and 2 are thought to interact with aromatic regions on guest molecules through π-
π interactions. It is thought that like the CDs and the CB[n]s, Motor1 and 2 maintain an 
equilibrium between bound and unbound drug, thus the factors that influence the release 
of the drug are as stated before. Both these compounds were found to have low self-
association, thus reducing the probability of host aggregation.  Motor1 and 2 are currently 
patented[167]. 
Motor1 is highly soluble up to 105 mM in phosphate buffer (20 mM) due to the 
four sulfonate groups attached at either end of the molecule (Figure 5). Phase solubility 
studies conducted by the Isaacs group have shown tremendous increases in drug 
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solubility upon binding to Motor1 even, and especially, in comparison to HP-β-CD 
(Table1). For example, PTX conjugated with Motor1 results in a 2750-fold increase 
(Figure 6A; 0.004 mM to 11 mM) in the drug’s solubility. Similarly, the complexation of 
Motor1 with ABZ increases its solubility by 226-fold (Figure 6B; 0.03 mM to 6.78 mM) 
and complexation of Motor1 with clopidogrel (anticoagulant) results in a 1220-fold 
increase in solubility (Figure 6C; 0.004 mM to 4.88 mM)[150].  
Motor1 was shown to most significantly enhance the solubility of paclitaxel 
which was surprising (Figure 6A). This is because paclitaxel is a neutral drug and also the 
largest the Isaacs group had tested. These results demonstrated Motor1’s great structural 
flexibility and it ability to bind to neutral, aromatic compounds through π-π interactions 
and the hydrophobic effect. Furthermore, it is thought that Motor1 forms hydrogen bonds 
with paclitaxel instead of ion-dipole interactions. These results are significant because 
they demonstrate the great diversity of pharmaceutical compounds Motor1 can possibly 
encapsulate.  It should also be noted that the phase solubility diagram of paclitaxel 
showed linear regions at lower concentrations of Motor1 and curved upwards at higher 
concentrations. This kind of phase solubility diagram is called an Ap-type plot and 
suggests a near 1:1 binding ratio of Motor1:paclitaxel for the linear regions and the 
presence of higher order complexes such as two Motor1 molecules to one paclitaxel 










Figure 5: Motor1 is an acyclic member of the CB[n] family with four glycouril units in 
its backbone and four sulfonate groups at either end which make it highly soluble (105 
mM) in aqueous solution. Linear chemical Structure (A) and folded x-ray crystal 











Figure 6: Motor1 significantly increases the solubility of several drugs like PTX (A; 
~2750-fold increase), ABZ (B; ~226-fold increase), and clopidogrel (C; ~1220-fold 








Motor2 has large aromatic groups attached at the ends of a chain of 6 glycouril 
units (Figure 7). This results in a lower intrinsic solubility at 14 mM in phosphate buffer 
(20 mM) but it also allows guest molecules to bind more easily and tightly to Motor2. 
This results in the need for lower concentrations of host molecules to significantly 
increase the solubility of guest molecules. CPT coupled with Motor2 results in a 580-fold 
increase in the drug’s solubility (Figure 8A; 0.02 mM to 11.6 mM) whereas an increase 
in drug solubility was barely detectable upon coupling with HP-β-CD (Table1). 
Furthermore, this increase in drug solubility was accomplished with only 10 mM of 
Motor2 while Motor1 conjugations necessitate a concentration upwards of 50 mM. ABZ 
conjugated to Motor2 results in a 149-fold increase in the drug’s solubility (Figure 8B; 
0.03 mM to 4.48 mM) and finally tamoxifen bound to Motor2 results in a 118-fold 
increase in drug solubility (Figure 8C; 0.01 to 1.18 mM). 
Motor2 binds to CPT at an ideal 1:1 ratio between host and drug as seen in the 
linear region of the phase solubility curve (Figure 8A), however, with several other drugs, 
a plateau was seen at higher concentrations of Motor2. This is known as an AN-type plot 
and suggests Motor2 self-association at higher concentrations. As stated before, Motor2 
may have lower solubility, however, it also binds to many drug compounds, like CPT, 
with very high affinity, thus potentially inhibiting the drug’s release. This does not, 
however, render Motor2 useless. It may be possible to use Motor2 for targeted delivery of 
drugs that requires the encapsulation of the drug within the carrier until the system 
reaches the necessary binding site. This will be discussed further later on in this thesis. In 
taking advantage of its high affinity to drugs, Motor2 is currently being studied by Dr. 
Matthias Eikermann (Massachusetts General Hospital and Harvard medical School, 
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Boston, MA) for the purpose of harvesting of neuromuscular blocking agents in vivo to 




) to the neuromuscular 
blocking agent rocuronium. By binding to rocuronium in blood, Motor2 depletes the 
concentration of the drug at the neuromuscular junctions, thus reversing the anesthetic 
effects. Once bound, Motor2-rocuronium is cleared from the body. Sugammadex, a 
derivative of γ-CD, has been marketed in Europe for this same purpose but it has not 
been approved for use in the US because of its potential to cause severe allergic reactions 





. Motor2 The advantages Motor2 has over Sugammadex allows 























Figure 7: Motor2 is an acyclic member of the CB[n] family with six glycouril units in its 
backbone and four sulfonate groups in addition to large aromatic groups at the ends 
[150]. Linear chemical Structure (A) and folded crystallography structure (B). Work done 









Figure 8: Motor2 significantly increases the solubility of several drugs such as CPT (A; 
~580-fold increase), ABZ (B; ~149-fold increase), tamoxifen (C; ~118-fold increase). 








Though the molecular properties of Motor2 are discussed, all biological data 
presented here will be using Motor1. This is primarily because Motor1 provided with the 
highest solubility and ideal binding affinities towards multiple drugs that would allow for 
their in vivo release.  
The above data provides encouraging proof that CB[n]-type molecular 
compounds can be used to improve the solubility of drugs that are failing the drug 
development pipeline for this reason. By doing so, they will not only improve attrition 
rates, but also enhance public health by providing a larger diversity of drugs in the market 
across therapeutic fields. Based on these molecular properties in addition to the success 
of other CB[n] compounds and their close counterparts, the CDs, I hypothesized that 
Motor1 can be used as an excipient to increase the solubility of many candidate and 
marketed drugs, thereby, improving their bioavailability and the easy with which these 












Chapter 3. PROJECT 1 MATERIALS AND METHODS 
3.1 Materials  
PTX was purchased from LLC Laboratories. CPT and ABZ were purchased from VWR. 
PBS-1086 was a gift from Dr. Timothy Fouts (Profectus Biosciences Inc., Baltimore, 
MD). Hoechst33342 was obtained from Sigma-Aldrich. Prolong Gold Antifade Agent, 
AlexaFluor-555 Phalloidin and Trypsin/EDTA were purchased from Invitrogen. CellTiter 
96 AQueous Kit® (MTS) was purchased from Promega and the Toxilight® BioAssay Kit 
(AK) from Lonza. Cell Death Detection ELISA® was purchased from Roche®. BD 
Matrigel™ was purchased from BD Biosciences. Analytical instruments used in this 
study included Spectramax M5e (Molecular Devices), Bio-TEK Synergy HT plate reader, 
Leica SP5 X Confocal, and BD FACSCanto II.  
 
3.2 Methods 
Cell and Bacterial Culture.  
HEK293 cells (Human Embryonic Kidney, ATCC #CRL-1573) were grown in DMEM 
(GIBCO media Invitrogen) with 10% heat inactivated fetal calf serum (FCS, Hyclone), 
and 1% Penicillin/Streptomycin (Invitrogen). HepG2 (Heptacellular carcinoma, Human, 
ATCC #HB-8065), HeLa (Human cervical carcinoma cells, kindly provided by Dr. David 
Mosser) and MCF-7 (Mammary Gland Adenocarcinoma, ATCC #HTB-22) cells were 
grown in MEM media (ATCC #30-2003) with 10% FCS and 1% Penicillin/Streptomycin. 
THP-1 (Blood Monocytes, ATCC #TIB-202) cells were grown in RPMI media (ATCC 
#30-2001) with 10% FCS and 1% Penicillin/Streptomycin. SKOV-3 (Ovarian 
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Adenocarcinoma, ATCC #HTB-77) cells were grown in McCoy's (ATCC #30-2007) 
with 10% FCS and 1% Penicillin/Streptomycin.  
Blood samples (50 mL) were collected from three healthy volunteers (University of 
Maryland IRB protocol #06-0218). M. smegmatis was cultured as described in 
Velmurugan et al [169]. 
 
Animal Studies 
Maximum tolerated dose (MTD) studies were performed at the University of Maryland, 
Greenbaum Cancer Center Translation Laboratories, Baltimore, MD under the 
supervision of Dr. Rena Lapidus (IACUC protocol #0405001). A total of 30 Female 
Swiss Webster mice were obtained from University of Maryland, Baltimore.  
Tumor studies were conducted at the University of Maryland, College Park, MD. 
NCrNU-F mice were purchased from Taconic (protocol# R-09-35). 
 
3.2.1 In vitro and in vivo assessment of Motor1 biocompatibility.  
Cell Viability and Cytotoxicity Assays 
HEK293 cells (2.5×10
6
), HepG2 cells (4×10
5
) and THP-1 cells (2.5×10
6
) were seeded in 
a 96 well plate (Corning) at 200 μL/well. After the cells were allowed to adhere for 24 
hrs, they were treated with 0.010, 0.1, 1 and 10 mM of Motor1 over a 48 hr period. Six 
technical replicates were used for the untreated samples while four technical replicates 
were used for all treatment samples including the distilled water treatment conducted 
before the cells were assayed. Cells were assayed using the MTS and AK assay according 
to vendor instruction. The AK assay was conducted by aliquoting 20 μL of supernatant 
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from each sample into a separate black well plate (Corning) after the 48 hr treatment 
period. These samples were run prior to using the MTS assay. The plates were read using 
the Spectramax M5e (Molecular Devices) and Bio-TEK Synergy HT plate reader. Data 
was collected in the form of units of absorbance and luminescence and normalized to 
percent cell viability (MTS) and percent cell death (AK) with the use of equations (1) and 
(2):  
% Cell Viability = (Abssample/Average AbsUT) × 100                                                        (1)      
% Cell Death = (RLUsamples/Average RLUdistilled water) × 100                                             (2) 
 
Hemolysis Assay  
Red blood cells (RBCs) were collected from 3 healthy donors and purified by 
centrifugation of whole blood at 1,200g for 15min. RBCs were then incubated with 
varying concentrations of Motor1 for 3 hours at a 1:10 dilution. Concentrations of 
Motor1 used were 0.01, 0.1, 1 and 1 mM. Hemolysis was evaluated by measuring 
absorbance at 540 nm. Percent hemolysis was normalized using equation (3). 
% Hemolysis = (Abssample/Average Absdistilled water) × 100                       (3) 
 
In vivo Toxicology 
Thirty female Swiss Webster mice were used for this MTD study. Five different 
concentrations of Motor1: 154.1 mg/kg, 308.2 mg/kg, 616 mg/kg, 924.6 mg/kg and 1230 
mg/kg were used including a PBS control group. Each concentration and the control 
group included 5 mice/group. Mice were dosed at 10 ml/kg according to their weights 
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once every 4 days for 8 days and were then monitored for 2 weeks after administering the 
last dose. Mice were dosed by tail vein intravenous injection. 
 
3.2.2 Evaluation of drug efficacy upon loading into Motor1  
In Vitro Bioactivity and EC50 Studies. 
PTX 




) and SK-OV-3 cells (2×10
4
) were seeded in three 
well slides (Electron Microscope Science) and allowed to adhere overnight. Cells were 
then treated with different concentrations of PTX complexed to Motor1 (5 mM) for 24 hr, 
and then fixed and stained with AlexaFluor 555-Phalloidin and Hoechst33342 according 
to the vendor instructions. Control groups included untreated cells, staurosporine, and 
treatment with Motor1. Cells were then incubated with Prolong Agent® overnight at 4
o
C 
and analyzed using the Leica SP5 X Confocal microscope. Quantification was performed 
on three replicate wells for two independent experiments by counting a total of 500 cells 
per well and determining the fraction of fragmented nuclei.  
For EC50 studies using 1×10
4
 HeLa and 2×10
4
 SK-OV-3 cells were seeded in triplicates 
in 96 well plates, incubated with Motor1-PTX at various concentrations for 24 hrs. The 
Cell Death ELISA® was then performed. Prism Graph 5.0 best-fit, non-linear analysis 
was performed to calculate EC50 values. 
 
PTX, PBS-1086, CPT and ABZ 
Comparative bioactivity studies were conducted using HeLa cells seeded at 1×10
4
 cells in 
triplicates in 96 well plates. Drugs were stirred overnight at maximum solubilities in 5 
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mM of Motor1 and HP-β-CD solutions.  Dilutions were made from these stock solutions 
(1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, and 0 mM of Motor1 and HP-β-CD). Cells 
were incubated for 24 hrs with these solutions and the Cell Death Detection ELISA® was 
performed.  
 
 In vivo Tumor Treatment 
Sixty-five female NUDE mice were injected subcutaneously under the neck with 1×10
7 
cells/100 µl of HeLa cells (DMEM/BD Matrigel™). Tumors were allowed to grow until 
a volume of 150-200 mm
3
 prior to the start of treatment.  
Drug solutions were made with Motor1 at the following concentrations:  
PTX (55.6 mg/kg) + Motor1 (924.6 mg/kg)  
PBS-1086 (134.16 mg/kg) + Motor1 (894.8 mg/kg) 
CPT (5.22 mg/kg) + Motor1 (184.9 mg/kg) 
ABZ  (17.8 mg/kg) + Motor1 (924.6 mg/kg) 
Mice were injected 3 times, each 4 days apart i.v. through the tail vein. Mice were dosed 
by weight (10 mL/kg). Two days after the last dose, mice were dosed again every day for 
four days. One week after the last dose of this schedule, mice were dosed a third time 
three times, one/day, by weight, i.p. Tumor volume, mouse weight and survival were 
monitored throughout treatment and for 1 week after the final dose. Experimental 
endpoints were: 1500 mm
3 






3.2.3 Statistical Analysis.  
Experimental data were presented as means ±SD except where otherwise stated. The 
results were analyzed using two-tailed Student’s unpaired t-test with Graph Pad Prism 






















Chapter 4. PROJECT 1 RESULTS AND DISCUSSION 
 
4.1 In vitro and in vivo assessment of Motor1 biocompatibility. 
4.1.1 Motor1 is well tolerated in vitro in human erythrocytes and monocytic, kidney 
and liver cell lines  
The human kidney cell line (HEK293) treated with concentrations of Motor1 at 
0.01, 0.1, 1, and 10 mM resulted in an average of 92%, 96%, 89% and 79% cell viability 
in the MTS assay (Figure 9A). Distilled water treated samples were at an average of 0.2% 
cell viability. The AK release assay (Figure 9B) showed an average of 2%, 1%, 1% and -
2% AK release in 0.01, 0.1, 1 and 10 mM of Motor1. The AK assay revealed an average 
3% AK release in untreated samples. 
In the MTS (Figure 9C) assay, the human liver cells (HepG2) treated with 0.01, 
0.1, 1 and 10 mM of Motor1 resulted in an average of 104%, 100%, 102%, and 82% cell 
viability. Distilled water was at an average of 1% cell viability. The AK assay (Figure 
9D) conducted using the HepG2 cell line showed an average of 55% 56% 50% and 17% 
AK release after treatment with increasing concentrations of Motor1 (0.01, 0.1, 1, and 10 
mM respectively). Untreated samples revealed an average of 59% AK release.  
Human monocytes (THP-1 cell line) treated with Motor1 (0.01, 0.1, 1, and 10 
mM) showed an average of 98%, 142%, 145% and 112% cell viability in the MTS assay 
(Figure 9E). The distilled water treated samples resulted in an average of 0% cell 
viability. The AK assay (Figure 9F) showed an average of 17%, 5%, 4% and 2% AK 
release after Motor1 treatment (0.01, 0.1, 1, and 10 mM respectively). The untreated 
samples resulted in an average 20% AK release.  
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Finally, the hemolysis assay conducted using primary human red blood cells 
(Figure 9F) showed 4%, release of hemoglobin from erythrocytes treated with 0.01, 0.1, 
1, and 10 mM Motor1 respectively. The untreated samples showed an average 3% release 
of hemoglobin.   
MTS (Figure 10A) and AK assays (Figure 10B) conducted on HepG2 cell line 
using HP-β-CD (1, 5, and 10 mM) resulted in an average of 104%, 88% and 121%  cell 
viability and 13%, 11% and 11% AK release respectively. Treatment with 
cremophor®EL (8.75 and 17.5 mM) showed an average 18% cell viability at both doses 
and an average 47% and 56% AK  release respectively.  
 
4.1.2 Motor1 was well tolerated in vivo in female Swiss Webster Mice.  
Mice dosed with 154.1, 308.2, 616, 924.6, and 1230 mg/kg of Motor1 via bolus 
tail vein injection three times over 8 days and monitored for an additional two weeks 
showed a steady increase in weight from day 0 (Figure 11). No signs of sickness were 












Figure 9: Motor1 is non-toxic in human kidney, liver and monocyte cell lines and 
human erythrocytes. Plots of cell viability (MTS assay; A C, E) and cell death (AK 
release assay; B, D, F) obtained for Motor1 (0.01 mM, 0.1 mM, 1 mM, 10 mM) after 48 
hr incubation with three cell lines: HEK293 cells (A, B), HepG2 cells (C, D) and THP-1 
cells (E, F). Data presented in A-F are the average values from triplicate experiments and 
the corresponding standard deviation values. Hemolysis assay (G) conducted using 
purified human red blood cells diluted in phosphate buffered saline and then incubated 
with Motor1 for 3 hr. Data represents the average and standard deviation values from 
three replicate experiments with four donors. For all panels, unpaired t-test analysis was 
used (*P=0.01–0.05; **P=0.001–0.01; ***P < 0.001). Work done by Gaya Hettiarachchi 





Figure 10: HP-β-CD is non-toxic in human liver cells up to a concentration of 10 
mM while cremophor®EL is toxic at both 8.75 and 17.5 mM. Cell viability (A) and 
cell death (B) obtained for HP-β-CD (1 mM, 5 mM, and 10 mM) and cremophor®EL 
(8.75 mM and 17.5 mM) after 48 hr incubation with HepG2 cells. Data is representative 
of three replicate experiments. Unpaired t-test analysis was used (*P=0.01–0.05; 














Figure 11: Motor1 is highly biocompatibility in vivo. Female Swiss Webster mice (n=5 
per group) were dosed via the tail vein on days 0, 4 and 8 (* = dosing day) with PBS or 
different concentrations of Motor1. The normalized average change in weight per group 
is indicated. Error bars represent standard error of the mean. Work done by Gaya 















For the in vitro toxicology work, two complementary cellular assays were used: 
MTS (CellTiter96 AQueous Kit®) assay which measures cellular metabolism, and the 
AK (ToxilightBioAssay Kit®) assay which measures cell death via the release of the 
cytosolic enzyme AK into the supernatant. In the cell viability assay, the MTS reagent is 
internalized and hydrolyzed by metabolically active cells into a colorimetric compound 
which can then be measured by a spectrophotometer. Therefore, the amount of 
colorimetric compound that is synthesized is directly proportional to the amount of 
metabolically active cells present in the sample and, thus, serves as a quantification of 
cell viability[170]. The AK assay quantifies the release of AK from cells with damaged 
membranes. AK is a cytosolic enzyme that converts ADP to ATP providing an energy 
source for the cell. When cells undergo necrosis, the cell membrane ruptures releasing 
cytosolic proteins, like AK, into the sample supernatant. In the AK assay, ADP is 
converted to ATP by this released AK. ATP then converts luciferin to light by using 
luciferase as a catalyst. This luminescence assay, therefore, provides a quantification of 
the release of AK from necrotic cells. Therefore, the AK assay provides a quantification 
of cell death[171].    
There are some drawbacks to these assays. In the MTS assay, the production of 
false positives may be likely. If cells are in the process of dying, they may become highly 
metabolically active giving false positives. However, the following experiments were 
done over a matter of days, therefore, the likelihood that dying cells remain metabolically 
active over the lengthy incubation periods is unlikely. A drawback of the AK assay is that 
this assay is dependent on the amount of AK in the cytosol of the particular cell. The 
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concentrations of AK can differ from cell type to cell type thus resulting in varied results. 
We see this in effect in Figure 9D where the untreated HepG2 cells showed almost 60% 
cell death. This experiment was repeated several times and with other cell lines. This 
phenomenon was only observed with the HepG2 cell line.   
 Both assays were used to assess the biocompatibility of Motor1 (Figure 9) in 
three different cell lines: human kidney (HEK293), liver (HepG2), and monocytic (THP-
1) cell lines. Two of these cell lines, the HEK293 and HepG2 cells, are commonly used 
in drug toxicity studies because the kidney and liver are organs where substantial 
amounts of drugs accumulate for metabolism and clearance by the body. This makes 
these key locations at which toxicity could occur. The THP-1 cell line was used to 
investigate any detrimental effects of Motor1 towards immune cells upon intravenous 
injection. For similar reasons, the hemolysis assay (Figure 9F) was used to determine 
whether Motor1 induces red blood cell lysis following intravenous injections. This was 
an important assay to conduct because as previously stated, the CB[n] family’s closest 
relative, the CDs, leads to hemolysis by extracting red blood cell membranes of 
cholesterol[124]. 
These initial toxicology work suggests that Motor1 surpasses some of the most 
commonly used DDSs such as CDs and cremophor®EL. Motor1 resulted in high cell 
viability and low cell death up to a concentration of 10 mM in HEK293, HepG2, and 
THP-1 cell lines (Figure 9A-F). Furthermore, the hemolysis assay showed that Motor1 is 
non-toxic to red blood cells (Figure 9G) up to a concentration of 10 mM. A comparative 
toxicity study using HP-β-CD and cremophor®EL in HepG2 cells was also conducted 
(Figure 10). These compounds were incubated for 24 hrs with HepG2 cells at 
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concentrations up to 10 mM (HP-β-CD) and 17.5 mM (cremophor®EL). These 
experiments revealed no significant decrease in cell viability or increase in cell death 
(Figure 10A and B) upon incubation with HP-β-CD. These results are comparable to 
those collected in Motor1 testing. In contrast, cremophor®EL was found to be highly 
toxic at concentrations of 8.75 and 17.5 mM. The MTD study using Female Swiss 
Webster mice and Motor1 up to a concentration of 1230 mg/kg/dose revealed no decrease 
in body weight from day 0 or deviation from the rate of weight gain observed in the PBS 
control group (Figure 11). We were not able to establish an MTD value using this dosing 
schedule due to limitations with Motor1 solubility.  
 CD toxicity is well established; this family, including its derivatives, are been 
known to cause toxicity in erythrocytes by extracting red blood cell membranes of 
cholesterol. The in vitro hemolytic activity of this family (at 1 mM) is as follows: β-CD > 
α-CD > HP-β-CD > γ-CD >> HP-γ-CD ≥ HP-α-CD in erythrocytes [124, 128]. In this 
regard, Motor1 was demonstrated to be superior up to a concentration of 10 mM. CD 
toxicology in vivo has been well established as well. The most toxic side effect observed 
is the family’s hemolytic activity, however, severe kidney damage after in vivo parental 
administration of CDs in rats and dogs has also been observed[129]. This damage is 
thought to be a result of cholesterol/CDs complexes depositing in the kidney and forming 
crystals. Concentrations ranging from 100-400 mg/kg of HP-β-CD showed minor 
reversible histological changes in the kidneys and erythrocyte damage in animal models. 
However, it should be noted that this phenomenon is not observed in humans[124, 130]. 
HP-β-CD is, however, limited to 400 mg/kg (i.v) due to the emergence of reproductive 
and developmental toxicities. (SBE)-β-CD was shown to be generally non-toxic in 
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animals and humans, however, it is limited to approximately 5 g/kg (i.v) due to 
reproductive and developmental toxicities[128].  For comparative purposes, a rigorous 
(ex: daily i.v dosing), long term, in vivo testing of Motor1 at varied dosing schedules will 
need to be conducted to determine an MTD value for this compound.  
Motor1 also surpassed cremophor®EL in safety. The toxicity of cremophor®EL 
is also very well established both in vitro, in vivo and in human clinical trials. 
Approximately, 30 mL/m
2 
of cremophor®EL can be administered in humans with some 
safety over a 3 hr infusion[31]. The primary adverse reaction associated with this 
formulation is severe hypersensitivity which is thought to be brought on by complement 
activation. Other severe adverse effects include neurotoxicity and liver damage[29, 31]. 
In vitro assays have established complement activation in several tumor cell lines with 
only 2 µg/mL of cremophor®EL which is readily available in clinical dosing[30]. 
Furthermore, in vivo studies conducted in dogs showed significant histamine release 
leading to hypersensitivity[29]. This histamine release is observed and connected to 
cardiac toxicity in other in vivo models[30].  
Within the limits of this study, Motor1 showed to be an attractive alternative to 
currently used technologies, like CD derivatives or surfactants such as cremophor®EL. If 
in vivo efficacy of multiple Motor1-drug complexes can successfully be established, 
further toxicity studies will need to be conducted to firmly establish the biocompatibility 
of this compound in hopes of filing an IND with the FDA and move Motor1 into clinical 
trials. As introduced before, there are different forms of toxicity that the FDA requires 
testing for during preclinical screening for excipients, like Motor1. There are different 
toxicity assessments for short term, intermediate and long term use of an excipient. 
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Before clinical trials can be started, adequate information on an excipient’s acute and 
repeat dose toxicities, genetic toxicity, immunogenicity, reproductive and developmental 
toxicity must be collected[20, 26]. Assessing these types of toxicities utilizes both in vitro 
and in vivo assays and most of these in vivo studies will need to be done in one rodent 
model, usually in rats, and one non-rodent model. Many of these studies should be 
conducted in the future before an IND for Motor1 can be submitted to the FDA[5, 26].  
Acute toxicity refers to toxicity after single high dose[27]. This assessment is 
recommended for short term, intermediate and long term use of Motor1. A repeat dose 
study can also be conducted using escalating doses instead of a single dose study. Repeat 
dose studies are, however, required for intermediate and long-term usage of Motor1. 
These studies should have a duration of 1-3 months for intermediate usage and 6-9 
months for long-term usage of Motor1. These studies must conclude with histopathology 
work to evaluate any toxicities to vital organs such as the liver, kidneys, spleen etc.[27]. 
These studies should also try and establish an MTD value for Motor1 if possible. Repeat 
dose evaluation of both Motor1 and 2 in rats is already underway in a collaboration with 
Dr. Matthias Eikermann at Massachusetts General Hospital and Harvard Medical School, 
Boston,  MA[168]. 
The Ames test and assays like it are important in vitro studies to conduct to assess 
any potent mutagenic properties Motor1 might exhibit[20, 41, 43]. However, this assay 
has been known to give false positive and negative results. In addition, the Ames study 
utilizes salmonella which is not an ideal model for study of eukaryotic cells. Therefore, 
genetic toxicity studies should also be evaluated in mammalian cell assays like the mouse 
lymphoma assay, and in in vivo mouse studies by using, for example, the Muta® mouse 
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model or the micronucleus assay[41, 42, 44, 45]. Both of these methods are accepted and 
well utilized evaluations of compound genetic toxicity. If these results are positive, 
further testing will be required to assess whether the compound can be carcinogenic upon 
administration[43]. Carcinogenicity evaluation usually involves a two year study using 
two different rodent species[26, 39].  
The most relevant studies in immunological toxicity to focus on for Motor1 would 
be hypersensitivity and immunogenicity. Testing for these could be to monitored using 
ELISAs to detect and quantify the expression of specific cytokines like TNF-α, Interferon 
γ or antibodies such as IgE or IgM[27, 28]. These assays can be conducted using cell 
lines and animal models. Blood samples can be collected from rodent and non-rodent 
models that had been administered with increasing concentrations of Motor1. These 
samples can then be purified and the presence of cytokines and/or antibodies can be 
quantified[20, 28]. It is generally recommended to do immunotoxicity evaluation as part 
of a repeat dose study as well as a single dose study.  
Reproductive and development studies are not required by the FDA prior to the 
start of clinical trials as long as pregnant women are not enlisted in the trials. However, 
this assessment is required prior to Phase III trials and if child-bearing women will be 
part of the study[47]. Reproductive and developmental studies are long term assays that 
usually involve repeat dosing followed by histological evaluation of reproductive organs, 
sperm count, etc. Furthermore, repeatedly dosed mice need to be mated and the growth 
and development of the embryo and fetus needs to be recorded[47]. These studies will 
most likely not be conducted with Motor1 until absolutely necessary.  
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In addition to these studies, the FDA also has guidelines in evaluating toxicity to 
vital functions and organs such as cardiovascular function[27]. One in vitro assay that can 
study the effect of Motor1 on cardiovascular function is the hERG assay[20]. This assay 
assesses whether a compound can block the potassium ion channel that contributes to the 
electrical activity needed to beat the heart and keep regular rhythm. Intravenous 
administration of Motor1 requires the evaluation of hemolytic properties and plasma 
concentrations of creatinine levels at clinically relevant doses to evaluate potential 
muscle damage[20]. Though hemolytic properties of Motor1 have been assessed in the 
scope of this current study, higher concentrations will need to be evaluated to assess 
injection site specific toxicities.  
The majority of this future work should be conducted in the rat model before 
translation into non-rodent models, however, this work is much farther down the 
developmental pipeline in pursuit of FDA approval. A few studies that could be 
addressed in the near future are the genetic and immune toxicity evaluations. 
 
4.2 As a result of increased solubility, an increase in drug efficacy was observed 
upon loading into Motor1 
4.2.1 An increase in the efficacy of PTX is observed due to increased solubility once 
coupled with Motor1 
Human cervical cancer cells (HeLa) were incubated with a saturated solution of 
PTX (2 µM; Figure 12D) or with a solution containing PTX (0.6 mM; Figure 12E) 
solubilized with Motor1 (5 mM). Controls included untreated cells (Figure 20A), 
staurosporine treated (Figure 12B) and Motor1 alone (5 mM; Figure 12C). Cell death was 
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detected by morphological changes, which were highlighted by staining the actin 
skeleton, and nuclear fragmentation. Quantification of the percentage of cells with 
fragmented nuclei demonstrated that after 24 hrs less than 5% of PTX-treated cells 
showed fragmented nuclei, whereas close to 90% of cells treated with Motor1–PTX had 
fragmented nuclei (Figure 12F). Dose–response experiments using HeLa and SK-OV-3 
cells incubated with Motor1-PTX (Figure 12G, and H) revealed EC50 values of 0.7 µM 
and 0.8 µM respectively. 
The Cell Death Detection ELISA® was conducted using HeLa cells treated with 
Motor1 (5 mM), Motor1-PTX (0.6 mM), cremophor®EL (17.5 mM) and 
cremophor®EL-PTX (0.6 mM). Untreated cells resulted in an average 19% cell death 
while Motor1, Motor1-PTX, cremophor®EL, and cremophor®EL-PTX resulted in an 
average 21%, 69%, 61%, and 73% cell death (Figure 13).  
 
4.2.2 Anticancer drugs, PTX, PBS-1086, CPT and ABZ, bound to Motor1 showed 
significantly higher efficacy in HeLa cells than when these drugs were complexed 
with HP-β-CD.  
 Dose response studies using Motor1 and HP-β-CD encapsulating PTX, PBS-
1086, CPT and ABZ were conducted over a 24 hrs period in HeLa cells. An average of 
76%, 66%, 68% and 91% cell death was observed for PTX (Figure 14A), PBS-1086 
(Figure 14B), CPT (Figure 14C) and ABZ (Figure 14D) respectively at the highest 
concentrations of Motor1 (1 mM; red line) used. An average 52%, 24%, 29% and 43% 
cell death was observed for PTX (Figure 14A), PBS-1086 (Figure 14B), CPT (Figure 
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14C) and ABZ (Figure 14D) respectively at the highest concentrations of HP-β-CD (1 













Figure 12: Cell death induction assays performed on HeLa cells indicated an 
increase in PTX efficacy as a result of increased drug solubility upon loading into 
Motor1.  HeLa cells were incubated for 24 h with cell culture medium alone (A), 
staurosporine (1 µM) (B), Motor1 (5 mM) (C), PTX (2 µM) (D), a solution containing 
Motor1 (5 mM) and PTX (0.6 mM) (E). Nuclei are stained in green and actin in red.  
Percent of cells (F) with fragmented nuclei in A-E. Scale bar for all panels, 25 mm. EC50 
determination for Motor1–PTX on HeLa (G) and SK-OV-3 (H) cancer cells. Cells were 
incubated with solutions containing Motor1 (5 mM) and the indicated concentrations of 
PTX for 24 hrs. The average and standard deviation of cell apoptosis induction was 
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determined for six replicates and normalized to the amount of apoptosis detected in cells 
killed with the apoptosis inducer staurosporine (1 µM). The best-fit, nonlinear regression 
curve is indicated by the broken line. Unpaired t-test analysis was used (*P=0.01–0.05; 



















Figure 13: Motor1-PTX (M1+P) cytotoxicity in HeLa cells was as a result of PTX 
bioactivity whereas cytotoxicity observed in the cremophor®EL-PTX (C+P) is 
indiscernible from cremophor®EL alone toxicity. Roche® Cell Death ELISA® was 
conducted on HeLa cells after 24 hrs of continuous incubation with the compounds with 
the compounds. Conditions: UT = untreated (black), Stx = staurosporine (1 µM) (gray); 
M1 = 5 mM (red); M1+P: M1 = 5 mM, P = 0.6 mM (red pattern); C = cremophor®EL 
(17.5 mM)(blue); C+P: C = 17.5 mM, P = 0.6 mM (blue patterned). This is an average of 
two separate experiments. The unpaired t-test analysis was used (*P = 0.01–0.05; **P = 












Figure 14: Cell Death ELISAs® performed on human cervical cancer cells using 
PTX, PBS-1086, CPT and ABZ conjugated to Motor1 or HP-β-CD indicated 
enhanced cytotoxicity with Motor1. HeLa cells were incubated for 24 hrs with PTX 
(A), PBS-1086 (B), CPT (C), ABZ (D) conjugated to Motor1 (red) or HP-β-CD (blue). 
The average and standard deviation of cell apoptosis induction was determined for four 
replicates and normalized to the amount of apoptosis detected in cells killed with the 
apoptosis inducer staurosporine (1 µM). This is representative of two repeat experiments. 
Unpaired t-test analysis was used (*P=0.01–0.05; **P=0.001–0.01; ***P < 0.001). 
Statistical analysis was done in comparison of Motor1 to HP-β-CD at each concentration. 




4.2.3 In vivo treatment using Motor1-PTX, Motor1-PBS-1086, Motor1-CPT and 
Motor1-ABZ against HeLa cell tumors showed promising efficacy in Motor1-PTX 
and Motor1-PBS-1086 treated mice.  
 Mice were given subcutaneous injections of HeLa cells under the neck skin and 
tumors were allowed to grow to approximately 150-200 mm
3
. Treatment was conducted 
using three different administration methods. PBS and Motor1 alone treatments are 
indicated in black and green lines respectively in all figures. 
 
Administration Method 1:  3 i.v doses, each one 4 days apart – last dosing on day 9. 
On the last day of treatment (day 9), tumor volumes showed an average of 
1110(±170), 1300(±220), 845(±230), 740(±174), 933(±242), and 951(±219) mm
3
 for 
PBS (Figure 15), Motor1 (Figure 15), PTX (Figure 15A), PBS-1086 (Figure 15B), CPT 
(Figure 15C), and ABZ (Figure 15D) conjugated to Motor1 respectively. Mouse weights 
were an average of 1.06 (±0.05), 1.07 (±0.07), 1.03 (±0.06), 1.04 (±0.06), 1.07 (±0.06), 
and 1.08 (±0.07) for PBS (Figure 16), Motor1 (Figure 16), PTX (Figure 16A), PBS-1086 
(Figure 16B), CPT (Figure 16C), and ABZ (Figure 16D) conjugated to Motor1 
respectively.  At this point, mouse survival rates were 100% for all treatments (Figure 
17A-D). 
 
Administration Method 2: 4 i.v doses, once daily – first dosing day 11, last dosing day 14 
At the end of 11 days, mouse survival (Figure 17) stood as such for each of the 
treatments: 90% survival for PBS, 40% survival for Motor1, 100% survival for all other 
treatments. Mouse change in weight (Figure 16) from day 0 was an average of 1.06 
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(±0.05) 1.08 (±0.07), 1.05 (±0.06), 1.03 (±0.07), 1.06 (±0.05), and 1.09 (±0.08) for PBS, 
Motor1, Motor1-PTX, Motor1-PBS-1086, Motor1-CPT, Motor1-ABZ on day 11 and 
tumor volumes were 1159 (±225), 1203(±55), 849(±196), 820(±208), 863(±192), and 
1054(±212) mm
3
 respectively (Figure 15). Further treatment continued with an altered 
dosing regimen, starting on day 11.  
At the end of this dosing schedule (day 14), tumor volumes were as such: 1472, 
768(±107), 799(±111), 839(±348), and 999(±241) mm
3
 for PBS (Figure 16), Motor1-
PTX (Figure 15A), Motor1-PBS-1086 (Figure 15B), Motor1-CPT (Figure 15C), and 
Motor1-ABZ (Figure 15D). Mouse weights had changed an average of 1.08, 1.03(±0.06), 
1.02 (±0.06), 1.00(±0.07), 1.04(±0.06) from day 0 for PBS (Figure 16), Motor1-PTX 
(Figure 16A), Motor1-PBS-1086 (Figure 16B), Motor1-CPT (Figure 16C), and Motor1-
ABZ (Figure 16D). Mouse survival at day 14 was 10% (PBS; Figure 17), 0% (Motor1; 
Figure 17), 90% (Motor1-PTX; Figure 17A), 90% (Motor1-PBS-1086; Figure 17B), 
100% (Motor1-CPT; Figure 17C), and 60% (Motor1-ABZ; Figure 17D) survival. 
 
Administration Method 3: 4 i.p. doses, once daily – first dosing day21, last dosing day 24 
At the start of this treatment on day 21, average tumor volumes (Figure 15), 
changes in weight (Figure 16), and percent survival (Figure 17) were as follows for 
Motor1-PTX, Motor1-PBS-1086, Motor1-CPT, and Motor1-ABZ: 998(±230), 
1098(±131), 1133(±109), and 1245(±173) mm
3
; 0.99(±0.05), 1.01(±0.02), 0.99(±0.04), 
and 1.04(±0.04); 50%, 50%, 30% and 50% survival.  
On the last dosing day, tumor volumes (Figure 15) were at an average of 
982(±101), 1038(±142), 1190(±21), and 1231 (±125) mm
3
 for Motor1-PTX, Motor1-
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PBS-1086, Motor1-CPT, and Motor1-ABZ respectively. Weight change (Figure 16) and 
percent survival (Figure 17) was: 0.92(±0.02), 0.98(±0.02), 0.99(±0.02), and 0.99(±0.02); 
50%, 50%, 30% and 30% survival in Motor1-PTX, Motor1-PBS-1086, Motor1-CPT, and 
Motor1-ABZ respectively.  





















Figure 15: Motor1-PTX (A) and Motor1-PBS-1086 (B) treatments showed 
significant stabilization of HeLa cell tumors in NUDE mice compared to PBS, 
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Motor1, Motor1-CPT (C) and Motor1-ABZ (D). 60 female NUDE mice were injected 
subcutaneously with 1×10
7
 cells/100 µL of HeLa cells. Tumors were allowed to grow to 
approximately 150-200 mm
3
 prior to using three methods of treatment. First dosing 
schedule: tail vein i.v dosing three times, once every four days. Second dosing schedule: 
tail vein i.v dosing four times, once every day. Third dosing schedule: i.p dosing four 
times, once every day. All mice were sacrificed on day 30. Treatments were PBS (black), 
Motor1 (green), Motor1-PTX (A; red), Motor1-PBS-1086 (B; red), Motor1-CPT (C; red), 
Motor1-ABZ (D; red). Starting n= 10 mice, changes in ‘n’ value for treatment group 

















Figure 16: Mice in all treatment groups maintained healthy weights until day 21 
when tumor sizes were 1000 mm
3
 or more and i.p dosing was started. 60 female 
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NUDE mice were injected subcutaneously with 1×10
7
 cells/100 µL HeLa cells. Tumors 
were allowed to grow to approximately 150-200 mm
3
 prior to using three methods of 
treatment. First dosing schedule: tail vein i.v dosing three times, once every four days. 
Second dosing schedule: tail vein i.v dosing four times, once every day. Third dosing 
schedule: i.p dosing four times, once every day. Treatments were PBS (black), Motor1 
(green), Motor1-PTX (A; red), Motor1-PBS-1086 (B; red), Motor1-CPT (C; red), 
Motor1-ABZ (D; red). All mice were sacrificed on day 30. Starting n = 10 mice, changes 
in ‘n’ value for drug treatment group indicated; *= i.v dosing; #=i.p dosing. Work done 


















Figure 17: All treatments with Motor1, especially with PTX and PBS-1086 extended 
mouse survival in comparison to PBS and Motor1 treatments. 60 female NUDE mice 
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were injected subcutaneously with 1×10
7
 cells/100 µL. Tumors were allowed to grow to 
approximately 150-200 mm
3
 prior to using three methods of treatment. First dosing 
schedule: tail vein i.v dosing three times, once every four days. Second dosing schedule: 
tail vein i.v dosing four times, once every day. Third dosing schedule: i.p dosing four 
times, once every day. All mice were sacrificed on day 30. Treatments were PBS (black), 
Motor1 (green), Motor1-PTX (A; red), Motor1-PBS-1086, Motor1-CPT (C; red), 
Motor1-ABZ (D; red). Starting n= 10 mice, changes in n value for drug treatment group 
indicated. The logrank statistical analysis was conducted. * = i.v dosing; # = i.p dosing; 
^P = 0.01–0.05; ^^P = 0.001–0.01; ^^^P < 0.001. Work done by Gaya Hettiarachchi and 






















Treatment of human cervical (HeLa) and ovarian (SKOV-3) cancer cell lines with 
Motor1-PTX showed that the increased concentrations of PTX being delivered to the 
cells as a result of Motor1 encapsulation enabled for more efficient killing of both types 
of cancer cells (Figure 12). This study also demonstrated that binding of PTX inside 
Motor1 does not interfere with the bioactivity of the drug. The quantification of 
fragmented nuclei post treatment clearly showed a significant difference in Motor1-PTX 
vs. PTX alone. 5 mM of Motor1 was able to solubilize 0.6 mM of PTX; this resulted in 
significantly higher levels of cytotoxicity when compared to the maximum solubility of 
PTX (0.002 mM) (Figure 12F). The EC50 values (Figure 12G and H) established in this 
study were comparable to those of Taxol® (1.7 µM[172]) indicating equal, if not slightly 
improved efficacy. However, the difference lies in the fact that cytotoxicity in Taxol® 
can, in large part, be attributed to cremophor®EL and not only PTX as demonstrated in 
cell death studies using HeLa cells (Figure 13). These cytotoxicity studies clearly 
indicated that the cell death observed by Motor1-PTX was as a result of drug bioactivity 
while Taxol® activity may have been primarily due to cremophor®EL. 
In vitro comparative bioactivity studies with four different anticancer drugs 
(Figure 14A-D) encapsulated in Motor1 and HP-β-CD were conducted to confirm 
whether increases in drug solubility using these DDSs can, in fact, result in increased 
bioactivity in other drugs. These studies also provided information on whether the 
encapsulation of these drugs in Motor1 can in any way inhibit their bioactivities. Studies 
were conducted with: PTX, PBS-1086, CPT and ABZ.  
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PTX is soluble up to 0.6 mM in 5 mM of Motor1, whereas no detectable increases 
in solubility were observed when PTX was coupled with 10 mM of HP-β-CD (Table 1). 
It is clear that Motor1 can significantly increase the solubility of this drug while HP-β-
CD cannot. This increase in solubility was somewhat translated into increased PTX 
bioactivity in HeLa cells using Motor1 vs. HP-β-CD showing an average of 76% cell 
death vs. 52% cell death respectively (Figure 14A). More striking differences were seen 
in the comparative treatment of PBS-1086, CPT and ABZ with Motor1 vs. HP-β-CD.  
 Motor1 was able to increase the solubility of PBS-1086 from undetectable levels 
to 7.5 mM in 10 mM Motor1. Encapsulation of PBS-1086 in 20 mM HP-β-CD did not 
provide any detectable increases to drug solubility (Table 1). These results were clearly 
reflected in the comparative bioactivity study conducted using HeLa cells. PBS-1086 
encapsulated with 1 mM of Motor1 showed an average of 66% cell death while 
encapsulation of the drug with 1 mM HP-β-CD showed only approximately an average of 
24% cell death which was not an improvement from the cytotoxicity of PBS-1086 
treatment alone (Figure 14B).  Out of all four bioactivity studies conduct, this was the 
most striking.   
 Motor1 at a concentration of 10 mM can solubilize approximately 0.91 mM of 
CPT while 10 mM of HP-β-CD can only solubilize 0.1 mM CPT (Table1). This, almost 
10-fold, difference in solubility is reflected in the bioactivity study where 68% cell death 
was observed in the most concentrated Motor1-CPT treatment than with the most 
concentrated dosing of CPT-HP-β-CD (29% cell death) (Figure 14C). 
 ABZ is soluble up to 1.86 mM in 10 mM of Motor1 and 0.2 mM in 10 mM of 
HP-β-CD (Table 1). This difference was again translated into drug bioactivity in the cell 
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death ELISA® with a 91% cell death in Motor1-ABZ (1 mM) while only 43% cell death 
was observed with ABZ-HP-β-CD (1 mM) (Figure 14D).  
 These comparative bioactivity studies showed that Motor1 can, in fact, solubilize 
drugs that HP-β-CD cannot and this ability to deliver higher concentrations of the drug 
leads to more efficient killing of HeLa cells in vitro. This data supports that Motor1 is an 
excellent counterpart to HP-β-CD when solubilizing and delivering anticancer drugs 
PTX, PBS-1086, CPT and ABZ. Further study will also need to be conducted in order to 
understand how Motor1 will compare to other forms of delivery such as liposomes, 
dendrimers and other forms of the CD family such as β-CD or Captisol®. 
As promising as these results may be, they do not, of course, mean that Motor1 
can increase the bioactivity of a drug in vivo. In vivo treatment introduces a multitude of 
variables, such as pH, blood proteins and enzymes, macrophages, etc., that can affect the 
activity of the drug, its release from Motor1, biodistribution, and other factors that 
determine the rate and extent to which the drug will reach its necessary site of activity[67, 
69, 73]. Therefore, extensive in vivo studies will need to be conducted before conclusions 
can be made. Here, I conducted a small scale tumor treatment study to begin to evaluate 
the practicality of using Motor1 as a drug delivery system.  
This very initial pilot study of in vivo tumor treatment using drug conjugated 
Motor1 was an opportunity to discover the optimal dosing schedule and administration 
method for the each of the drugs used with Motor1: PTX, PBS-1086, CPT, and ABZ. 
Therefore, several different dosing schedules and administration methods (both i.v dosing 
and i.p) were used. This study was also conducted with the purpose of selecting the most 
effective treatments to conduct more thorough studies using the ideal dosage schedule 
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and comparative bioactivity using other delivery systems such as HP-β-CD or Captisol® 
for example. The study was conducted using 60 female NUDE mice that were injected 
subcutaneously with HeLa cells. Tumors were allowed to develop to a volume of 
approximately 100-250 mm
3
, after which time treatment of these tumors commenced 
using PBS, Motor1 alone (924.6 mg/kg), PTX(55.6 mg/kg)-Motor1, PBS-1086(134.2 
mg/kg)-Motor1, CPT(5.2 mg/kg)-Motor1 and ABZ(17.8 mg/kg)-Motor1. Each dosing 
group consisted of 10 mice (Figure 15-17).  
 
Administration Method 1: 3 i.v doses each 4 days apart.  
In the first dosing schedule, mice were dosed through the tail vein, by weight 
(10ml/kg) 3 times, each one four days apart. Upon monitoring tumor volume and body 
weight, this dosing regimen did not yield any decrease in body weight. On the last day of 
treatment (day 9) with Motor1-PTX (845 ±230 mm
3
; Figure 15A) and Motor1-PBS-1086 
(740±174 mm
3
; Figure 15B) seemed to indicate some slowing in tumor growth rate in 
comparison to the tumor growth of mice treated with Motor1-CPT (933±242 mm
3
; Figure 
15C), Motor1-ABZ treated (951±219 mm
3
; Figure 15D), Motor1 (1300±220 mm
3
; Figure 
15; green) and PBS (1110±170 mm
3
; Figure 15; black). During this treatment schedule, 
more striking differences were not observed for two possible reasons: 1) HeLa cells make 
for very aggressive tumors[173, 174], which means that 2) an equally aggressive 






Administration Method 2: 4 i.v doses, once daily dose.  
 Therefore, two days after the last dosing of the first administration method, the 
mice were dosed through i.v for four days consecutively with the same treatment samples 
at 10 ml/kg. At the end of this dosing schedule (day 14) a stabilization of tumor volume 
where no significant increase or decrease of tumor volume was observed in the treated 
mice (Figure 15). No significant weight loose was observed on this dosing schedule, 
however, it should also be noted that there was a stabilization of weight change during 
this treatment schedule (Figure 16). Mouse survival (Figure 17) at this point decreased 
significantly for those treated with PBS (10% survival) and Motor1 (0% survival). The 
tumors in these mice grew to 1500 mm
3
, at which point they were sacrificed. Therefore, 
even though a decrease in tumor volume may not have occurred, the treatments 
significantly extended the life span of these mice. Though this dosing regimen yielded 
more promising results in the Motor1-PTX and Motor1-PBS-1086 treatments, continued 
i.v. dosing was not possible, due to difficulty in injecting as a result of extensive scar 
tissue. Mice were allowed to recover for a week. During this time, tumors started to grow 
in volume (Figure 15).  
 
Administration Method 3: 4 i.p doses, once daily dose.  
In order to continue dosing and to check Motor1-drug efficacy, we decided to 
continue to dose the mice by weight with the same treatments on a daily schedule using 
i.p administration. This method is extensively used in pilot in vivo studies to establish 
dosing schedules and determine MTD values for treatments in cancer research[175]. This 
is in large part due to the fact that extended daily dosing can be conducted easily and 
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effectively because i.p administration in the animal model has been shown to closely 
mimic the bioavailability of i.v administered drugs. Tumor volumes were stabilized 
during this treatment, but some initial decrease in mouse weight was observed. This was 
thought to be a result of aggressive dosing and the presence of large aggressive tumors 
for an extended period of time. Mouse survival was at 50% for Motor1-PTX and Motor1-
PBS-1086 and 30% for both Motor1-CPT and Motor1-ABZ. This showed significant 
survival rates in mice treatment with Motor1-PTX and Motor1-PBS-1086 as opposed to 
Motor1-CPT and Motor1-ABZ.  
At the conclusion of this study, we found that Motor1-PTX and Motor1-PBS-
1086 demonstrated the greatest anti-tumor activity as shown by stabilization of tumor 
volumes and high survival rates. We also determined i.p dosing would be an effective 
alternate dosing method for future studies. Based on these studies and understandings, 
important future studies that will need to be conducted to further validate the use Motor1 
as an adequate solubilizing excipient. The first and foremost would be to adjust the 
dosing regimen and administration method. I.p dosing may be used as a daily dosing 
method, until either no measurable tumors are present or severe adverse effects set on. A 
second study that will need to be conducted is to test the effectiveness of these new drug 
formulations against a variety of different tumors. It should be noted that an aggressive 
dosing regimen can lead to excessive weight loss and sickness directly as a result of the 
treatment. Therefore, a more adequate solution to this dilemma may be to use an 
alternative less aggressive tumor model. The doses and dosing schedule will need to be 
revised accordingly. Using the optimal concentrations, form of administration and dosing 
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schedule are key in the success of these initial proof-of-principle in vivo studies and in 
elucidating the appropriate uses for Motor1.  
A second important study to include alongside these treatment studies is the 
evaluation of Motor1-drug pharmacokinetics or bioavailability through i.v and i.p dosing 
to both elucidate properties of the delivery complex as a whole and also to confirm that 
both dosing methods can present with equal bioavailability. This kind of experiment can 
be conducted by dosing mice or rats with Motor1-drug through i.v and i.p and collecting 
blood samples after 5 mins, 10 mins, 30 mins, 60 mins, 3 hrs, and onwards up to at least 
24 hrs. Blood will need to be collected through cardiac puncture (terminal procedure). 
From collected blood, Motor1, drug and Motor1-drug samples can be purified through 
HPLC methods (will be done by the Isaacs lab) and the concentrations of each can be 
determined in an attempt to understand its pharmacokinetics. Some of this work has 
already been initiated by Dr. Eikermann in rats.  
Though this initial tumor treatment study needs to be repeated under optimal 
conditions, it still provides some encouraging results towards the use of Motor1 as a 
DDS. Importantly, these results indicate that encapsulation in Motor1 does not inhibit the 
drug’s activity and the drug is, in fact, released from the delivery molecule. Further 
evaluation of Motor1-drug efficacy and pharmacokinetics will help determine dosage and 







































Chapter 5. PROJECT 2 INTRODUCTION  
 The three leading causes of attrition in the drug development pipeline are low 
drug efficacy (30%), high drug toxicity (11%) and low drug bioavailability (39%)[12]. 
One way to alleviate developmental attrition is to improve drug solubility using drug 
delivery systems as discussed before. However, there is another way, especially in cancer 
therapy, to reduce attrition rates. Chemotherapy involves the use of severely cytotoxic 
compounds that primarily target the replication and growth of cells to reduce or halt 
tumor growth. However, these drugs not only kill cancerous cells but also lead to severe 
side effects as a result of killing healthy cells[84, 91]. The targeted delivery of drugs 
specifically to diseased tissue can not only ensure that the drug gets to the necessary site 
of activity efficiently, in turn, improving bioavailability but also significantly reduce drug 
toxicity. Drugs that are specifically delivered to tumors would theoretically exhibit 
selective toxicity primarily limited to cancerous cells leaving normal cells healthy[84, 
90]. This would, in turn, significantly reduce the severe side effects associated with 
chemotherapy. Not only are there numerous candidate anti-cancer drugs in the pipeline 
that are dose or development limited by their high toxicities, there are also an extensive 
amount of approved and marketed chemotherapy drugs that are not as effective as they 
could be in tumor treatment because of their dose limiting toxicities[23]. Targeted 
delivery could allow for the safe increased dosage regiments rendering many anti-cancer 
drugs more effective.  
  In cancer therapy, there are two main forms of targeting: passive and active 
(Figure 18). Both these forms of targeting necessitate the use of drug delivery systems 





Figure 18: Passive targeting and active targeting of anticancer drugs to tumors. Passive 
targeting involves the filtering of compounds into irregular tumor vasculature based on 
their molecular properties. Active targeting entails the use of a tumor receptor-specific 






5.1 Passive Targeting 
 Passive targeting refers to the Enhanced Permeation and Retention (EPR) effect. 
The EPR effect is a well-known phenomenon that was first discovered and characterized 
by Hiroshi Maeda in 1986[94, 95]. When tumors form, their rapid growth results in the 
formation of irregular vasculature (Figure 18); this defective network of blood vessels 
enhances permeability into the tumor thus increasing the flow of nutrients and oxygen 
necessary for the rapid growth of the tumor [95]. EPR effect is defined by the fact that 
molecules of certain size and lipid composition are favored to enter and accumulate in 
this irregular vasculature[96, 98]. For example, macromolecules in the range of 10-500 
nm in size leak out of blood vessels and accumulate in tumor tissue[99, 176].  The EPR 
effect is a great advantage in chemotherapy because it not only allows for the selective 
delivery of anticancer drugs to tumors and therefore, selective cytotoxicity in cancer 
cells, but the EPR effect also enables these compounds to become trapped and 
accumulate within the tumor due to its defective drainage system[94]. In fact, some 
studies have shown that 24hrs to several days following i.v administration, 
macromolecules were at 10-200 times concentrations than normal tissue[95]. This 
retention of anticancer drugs allows for the drugs to be maintained at high concentrations 
within the tumor over an extended period of time resulting in increased drug efficacy.  
One important discovery that has helped researchers take advantage of the EPR 
effect is PEG[92, 177]. These polymers, depending on the number of chains used and 
their length, not only increases the systemic circulation of a compound, but also favors 
the EPR effect[178]. As a result, because most drugs do not naturally exhibit the 
properties needed to induce the EPR effect, they must either be directed conjugated to 
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PEG chains or drug delivery systems such as PEGylated liposomes must be used[102]. 
PEGylating drugs themselves without changing the efficacy or toxicity of the drug is very 
difficult, therefore, anticancer compounds, either in the developmental pipeline or those 
already marketed, are more often encapsulated in PEGylated DDS. One example of this 
is Doxil® which is now FDA approved and marketed. Doxil® is the trade name for the 
anticancer drug doxorubicin encapsulated in PEGylated liposomes known as 
STEALTH® liposomes[113, 179, 180]. Studies have shown that STEALTH® liposomes 
not only have improved pharmacokinetics as a result of extended systemic circulation, 
but more importantly, they exhibit reduced side effects as a result of selective drug 
toxicity[180] (60, 61). Another example is Genexol-PM®[103] which uses PEGylated 
micelles (currently in clinical trials).  
Though there are many advantages towards the use of the EPR effect, it is not 
without its problems. Even though the irregular vasculature of a tumor allows for 
increased macromolecule permeability, it also results in inadequate heterogeneous 
distribution of the drug throughout the tumor. Furthermore, individual tumors and certain 
tumor types vary in the extent of vasculature and permeability leading to variable results 
in treatment[95]. It was also discovered that the EPR effect is more prominent in smaller 
tumors (0.5-1cm) in vivo as opposed to larger tumors (1-2cm) which seems to be, in part, 
due to irregular vasculature. In an effort to circumvent these issues, Maeda et al have 
recently attempted to intensify the EPR effect in tumors where treatment had failed. One 
method they used was to increase blood pressure while another was to introduce nitric 
oxide releasing agents to expand the vasculature[95]. Both these methods have their 
disadvantages. Studies have also shown that PEG can elicit PEG-specific IgM production 
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which, in turn, activates complement in vivo after repeated dosings[101, 102, 181]. This 
leads to rapid blood clearance and significantly decreased bioavailability of the drug. 
PEGylated particles have also shown slower uptake by tumor cells in comparison to non-
PEGylated macromolecules which leads to increase systemic circulation time but also 
leads to decreased drug efficacy over time. This problem is known as the PEG dilemma. 
One way to address this problem could be to use linkages that could be cleaved by 
proteases one the cargo reaches tumor cells[182].  
 
5.2 Active Targeting 
An alternative to passive targeting is active targeting (Figure 18) which entails the 
use of ligands that are specific to receptors that are uniquely expressed or overexpressed 
on tumor cell surfaces. There are several examples of these targeting ligands that can be 
used such as monoclonal antibodies, prostate specific membrane antigen (PSMA), folate 
and biotin.  
PSMA is a type 2 integral membrane glycoprotein that is the single most tissue 
specific unsecreted surface antigen established to date[183]. The exact function of PSMA 
is still unknown, but it is found on all prostate cancers and its expression is significantly 
increased in higher grade prostate cancers, metastatic diseases and has also been found in 
the neovasculature of nonprostate tumor malignancies[183]. All these properties make it 
an ideal targeted for tumor specific delivery of therapeutics[184]. PSMA is generally 
targeted by using anti-PSMA monoclonal antibodies; one that is currently approved for 
human research is J591[183].  
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Several therapeutics conjugated to J591 are currently in clinical trials. 
Radioimmunotherapy (RIT) is a technique used for cancer therapy that involves the 
targeted delivery of a radionuclide, such as 177-Lutetium (
177
Lu), linked to a monoclonal 
antibody. One that is showing success in Phase II clinical trials is 
177
Lu-J591[183]. 
Furthermore, this antibody can be used to specifically deliver anticancer drugs such as 
Maytansinoid 1, a potent microtubule- depolymerizing compound. This compound is also 
currently in Phase II trials[185]. PSMA-targeted nanoparticles include dendrimers, 
liposomes, and micelles all of which have shown successful preclinical delivery to and 
killing of cancerous cells[74, 186]. Polymer encapsulated drugs have also been targeted 
with PSMA. In these instances, several studies have also been conducted using anti-
PSMA aptamers, such as A10 RNA, as targeting ligands instead of antibodies. One 
successful example of this comes from Dr. Omid Farokhad’s lab (Harvard Medical 
School, Boston MA), who has created two systems using polymer nanoparticles and A10 
RNA targeting mechanism to deliver the anticancer drug docetaxel (BIND-014; in 
clinical trials) and combination of cisplatin and doxorubicin which has demonstrated 
great preclinical success[74, 187, 188]. 
Two other extensively studied cancer specific target are the folate and biotin 
receptors. These receptors are found on all cell surfaces but are significantly 
overexpressed in many cancers such as breast and ovarian cancers. Folate and biotin are 
essential components in DNA synthesis, repair, methylation and overall cell growth. 
They are especially important during rapid cell division and growth which alludes to the 
overexpression of these receptors on the surface of cancer cells[84]. There are three folate 







). FOLR1 and 3 are particularly overexpressed in breast, uterine 
and ovarian cancers, however, FOLR1 is also overexpressed in lung, kidney and placenta 
cells. There are several examples of folate targeted nanoparticles in preclinical studies 
including dendrimers, liposomes and carbon nanotubes with anticancer drugs like 
doxorubicin, CPT, and methotrexate[84, 189, 190].  
Finally, biotin is not synthesized by human and mammalian cells but, instead, 
must be acquired through exogenous sources such as food and intestinal floral[191]. 
Biotin, like folate, is an essential nutrient necessary for DNA synthesis, cell replication 
and growth. Therefore, like folate, the receptor for biotin is expressed on all normal cells 
but is significantly overexpressed on cancer cells. Targeting with biotin is a quickly 
growing field of interested in drug delivery; this molecule is used in conjugation with 
several nanoparticles such as dendrimers, liposomes and polymer based nanoparticles and 
is also studied through direct conjugation of the nutrient to anticancer therapeutics[192-
194]. One example of this is biotin conjugated to the taxoid SB-T-1214[194].   
 
5.3 Biotin-CB[7] 
In this section of my thesis, I will discuss the use of a novel biotin functionalized 
CB[7] compound, created in Dr. Isaacs’ lab. This molecule will serve as a proof-of-
principle towards the use of CB[n]-type compounds for targeted delivery of drugs. CB[7] 
is probably the most extensively studied parent molecule from the CB[n] family due to its 
high intrinsic solubility (20 mM) and large cavity size. This new biotin-CB[7] compound 
has a solubility of approximately 1 mM, therefore, it may not lend much towards 
increasing the solubility of a drug (Figure 20). However, the unique property of this 
compound lies in its ability to target cells overexpressing the biotin receptor[151]. 
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Therefore, this host molecule can be used to actively target fairly soluble anti-cancer 
drugs to tumors thus significantly minimize any adverse side effects administering the 
drug alone may produce.  
For this study, the potent drug, oxaliplatin, was used to test the functionality of 
biotin-targeted CB[7]. Oxaliplatin is a first and second line form of therapy for many 
aggressive cancers. It works by binding to DNA and forming adducts thus halting DNA 
synthesis. However, as widely used as it is, oxaliplatin is dose limited by somewhat poor 
pharmacokinetics and severe side effects such as neurotoxicity and hypersensitivity[22, 
195]. Therefore, though this drug is essentially effective in combination therapy, there is 
significant room for improvement through targeted delivery. Furthermore, oxaliplatin has 
been successfully conjugated with CB[7] before [146, 196].  
 
5.4 Hypothesis 
Based on the promising studies in biotin targeted drug delivery conducted by 
other researches and the inherent properties of the biotin-CB[7] compound, I hypothesize 
that functionalized CB[n] and CB[n]-type particles, like biotin-CB[7] can be used to 
specifically localize and/or increase the uptake of anticancer agents by tumor cells 















Figure 19: Biotin targeted CB[7] is soluble up to 1 mM[151]. Work by Liping Cao and 









Chapter 6. PROJECT 2 METHODS AND MATERIALS 
6.1 Materials 
Oxaliplatin was purchased from Selleck Chemicals LLC. Hoechst33342 was obtained 
from Sigma-Aldrich. Dextran-Alexa647, Prolong Gold Antifade Agent, and 
Trypsin/EDTA were purchased from Invitrogen. FITC was purchased from…CellTiter 96 
AQueous Kit® was purchased from Promega and the Toxilight® BioAssay Kit from 
Lonza. Cell Death Detection ELSA was purchased from Roche®. Analytical instruments 
used in this study included Spectramax M5e (Molecular Devices), Bio-TEK Synergy HT 
plate reader, Leica SP5 X Confocal, and BD FACSCanto II.  
 
Cell and Bacterial Culture.  
RAW264.7 cells (Mouse leukemic monocyte macrophage, ATCC #TIB-71) and HEK 
293 cells (Human Embryonic Kidney, ATCC #CRL-1573) were grown in DMEM 
(GIBCO media Invitrogen) with 10% heat inactivated fetal calf serum (FCS, Hyclone), 
and 1% Penicillin/Streptomycin (Invitrogen). HepG2 (Heptacellular carcinoma, Human, 
ATCC #HB-8065), L1210/FR cells (murine lymphocytic leukemia cells, kindly provided 
by Dr. Iwao Oijma, State University of New York at Stony Brook, Stony Brook, NY) 









6.2.1 In vitro assessment of CB[7] biocompatibility.  
HEK293 cells (2.5×10
6 
cells/mL), HepG2 cells (4×10
5
 cells/mL) and RAW264.7 cells 
(8×10
4 
cells/mL) were seeded in a 96 well plate (Corning) at 200 μl/well. After the cells 
were allowed to adhere for 24 hrs, they were treated with increasing concentrations of 
CB[7] (0.01, 0.1 and 1 mM) for 48 hrs. Cells were assayed using the MTS and AK assay 
according to vendor instruction. The AK assay was conducted by aliquoting 20 μl of 
supernatant from each sample into a separate black well plate (Corning) after the 48 hr 
treatment period. These samples were run prior to using the MTS assay. The plates were 
read using the Bio-TEK Synergy HT plate reader. Data was collected in the form of units 
of absorbance and luminescence and normalized to percent cell viability (MTS) and 
percent cell death (AK) with the use of equations (1) and (2). 
 
6.2.2 Determination of the uptake and localization of CB[7] and biotin-CB[7] 
compounds in mammalian cells.   
CB[7]-Alexa 555 uptake and localization 
RAW264.7 cells were seeded in a 24 well plate (Corning) at 5×10
5
 cells/mL. All 
samples were done in technical quadruplets and then combined to form doublets per 
sample. Controls included untreated cells and cells treated with Alexa555 alone. The 
CB[7]-Alexa555 complex was incubated with cells at the respective concentrations for 20 
min and then collected for analysis. Cells were collected and fixed with 4% PFA before 
analysis by flow cytometry. For the time course assay, CB[7]-Alexa555 was again 
incubated with cells for 20 min at a concentration of 32 mM after which time the cells 
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were washed and incubated for 15, 20, 120 min with fresh medium (DMEM, and 10% 
FCS) before analysis by flow cytometry. 
For the intracellular localization study, RAW264.7 cells were seeded at 10
4
 
cells/200 µL in 3-well glass slides (Electron Microscopy Sciences). Controls included 
cells stained with Hoechst33342 staining alone, Dextran-647 alone and CB[7]-Dextran-
647 alone. Dextran-647 was incubated with cells overnight at a concentration of 125 
µg/mL. The CB[7]-FITC complex was incubated with cells for 20 min. at a concentration 
of 32 mM the following day and then chased with fresh growth medium for 15, 45, and 
120 min. Before analysis, cells were fixed with 4% PFA, washed and immobilized with 
Prolong® Gold Antifade Agent. 
 




cells/200 µL) were seeded in a 96-well plate and incubated 
with Dextran-647 (125 µg/mL) overnight at 37
0
C. The following day, the cells were 
washed and incubated with 2 µM and 15 µM of biotin-CB[7]-FITC and CB[7]-FITC for 
30 mins at 37
o
C. Cells were washed 3 times, fixed with 4% PFA and stained with 
Hoechst33342. Cells were washed again and transferred to 3-well slides (Electron 
Microscopy Sciences) prior to confocal imaging. Experiments were repeated three times. 
L1210FR cells (5×10
5
 cells/200 µL) were seeded in a 96-well plate and incubated 
with 2 µM and 15 µM of biotin-CB[7]-FITC and CB[7]-FITC for 1.5 hrs at 4
o
C. Cells 
were washed 3 times and chased with fresh media for 0, 15 and 30 mins at 37
o
C. Cells 
were then fixed with 4% PFA and stained with Hoechst33342. Cells were washed again 
113 
 
and transferred to 3-well slides (Electron Microscopy Sciences) prior to confocal 





 cells/200 µL of L1210FR and L1210 cells were plated in 96-well plate 
(Corning) and treated with CB[7]–FITC and biotin-CB[7]-FITC at a concentration of 2 
μM for 30 mins.  Treatment was conducted at 37
o
C. Cells were washed 3 times with PBS 
and collected for analysis by Flow Cytometry.  Each experiment consisted for two 
technical replicates and was repeated three times.  
Similarly, for the biotin competition assay, 5 ×10
5
 cells/200 µL of L1210FR and 
L1210 cells were plated in 96-well plate (Corning) and treated with increasing 
concentrations of Biotin (0.05-500 µM) for 30 mins. Cells were then washed twice and 
incubated with biotin-CB[7]-FITC at a concentration of 2 μM for 30 mins.  Treatment 
was conducted at 37
o
C. Cells were washed 3 times and collected for analysis by Flow 
Cytometry.  Each experiment consisted for two technical replicates and was repeated 
three times.  
 
6.2.3 In vitro evaluation of drug efficacy upon loading into CB[7] and biotin-CB[7].  
Ethambutol 
RAW264.7 cells were seeded at 5×10
5
 cells/mL in one well of a 24-well plate. As 
controls we examined untreated cells on day 0 and day 3. Each sample was tested in 
technical duplicates. Cells were infected with M. smegmatis at a multiplicity of infection 
(MOI) of 10:1 for 2 h and then incubated with chase media (infection media with varying 
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concentrations of EMB or CB[7]-EMB) for 3 days. The EMB and CB7-EMB were used 
at minimum inhibitory concentration (MIC) values of 0.1 (2.4 mM), 0.4 (9.6 mM), 0.8 
(19.2 mM) and 1 (24 mM) [53] units during M. smegmatis treatment. On day 3, cells 
were lysed with 1 ml/well of distilled water/0.05%Tween-80. The cell lysate for each 
condition was added to 7H9 (DifcoH Middlebrook) media. These solutions were then 
serially diluted four times and plated in technical triplicates of 5 mL each on 7H10 
(DifcoH Middlebrook) agar plates. Viable bacteria were quantified by calculating the 





 cells/200 µL of L1210FR cells were seeded in a 96-well plate (Corning). Cells 
were treated with increasing concentrations of oxaliplatin, CB[7]-oxaliplatin, and biotin-
CB7-oxaliplatin for 45 mins at 37
o
C. Cells were then washed twice with PBS and 
incubated with fresh growth medium for 24 hrs.  The plate was treated with CellTiter One 
AQueous Solution® at a 60:80 v/v ratio for 3 hours after which time the data was 
collected using Bio-TEK Synergy HT plate reader at an absorbance of 490 nm. The data 
was normalized to percent cell viability using equation (1).  Untreated samples were 
considered at 100% cell viability. This experiment included three technical replicates and 







6.2.4 Statistical Analysis.  
Experimental data were presented as means ±SD except where otherwise stated. The 
results were analyzed using two-tailed Student’s unpaired t-test with Graph Pad Prism 



















Chapter 7. PROJECT 2 RESULTS AND DISCUSSION 
 
7.1 In vitro assessment of CB[7] biocompatibility  
7.1.1 CB[7] is well tolerated in murine macrophage and human kidney and liver cell 
lines.  
The MTS and AK assays for all three cell lines, HEK293, RAW264.7 and 
HepG2, were conducted after two days of incubation with the CB[7] at concentrations of 
10 µM, 100 µM, and 1 mM (Figure 20). Relative absorbance and luminescence data was 
normalized to percent cell viability (MTS) and death (AK). In the MTS assay, the 
untreated samples were set at a 100% cell viability, while in the AK assay distilled water 
and CPT treated cells were set at a 100% cell death[145].  
In the MTS assay conducted using HEK293 (Figure 20A) cells, CPT treatment 
resulted in an average 59% decrease in cell viability. CB[7] at a 1 mM dose resulted in an 
average 94% cell viability. In the AK assay (Figure 20B), the untreated HEK293 cell 
population indicated only an average 18% cell death and CB[7] at a concentration of 1 
mM resulting in a comparable average of 9% cell death[145].  
In studies conducted in the liver cell line, HepG2, the MTS assay (Figure 20C) for 
distilled water treated HepG2 population indicated a percent cell viability of an average 
of 0.28% while treatment with 1 mM of CB[7] resulted in an average 96% cell viability. 
In the AK assay (Figure 20D), the highest concentration of CB[7] resulted in an average 
22% cell death in the HepG2 cell line.  
In RAW264.7 cells, the MTS assay (Figure 20E) for the CPT treated cell 
population resulted in a decrease in cell viability by an average of 99%. At a 1 mM 
concentration, CB[7] produced an average 101% cell viability. The AK assay (Figure 
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20F) showed the untreated population cell death equal to an average of 38% and CB[7], 

















Figure 20: CB[7] is non-toxic in human kidney and liver cell lines and murine 
macrophages. Plots of cell viability (MTS assay; A C, E) and cell death (AK release 
assay; B, D, F) obtained for CB[7] (0.01 mM, 0.1 mM, 1 mM) after 48 hr incubation with 
three cell lines: HEK 293 cells (A, B), HepG2 cells (C, D) and RAW264.7 cells (E, F). 
Data presented in A-F are the average values obtained from triplicate experiments and the 
corresponding standard deviation values. Data represents the average and standard 
deviation values from three replicate experiments with four donors. For all panels, 
unpaired t-test analysis was used (*P = 0.01–0.05; **P = 0.001–0.01; ***P < 0.001) 









The first step towards establishing a proof-of-concept for using CB[n]s and their 
derivatives for targeted delivery of drugs is to evaluate host toxicity. The MTS and AK 
assays were used here to evaluate in vitro biocompatibility. Three different cell lines were 
used: human kidney (HEK293), liver (HepG2), and a murine macrophage (RAW264.7) 
cell line. The importance of using these cell lines were discussed before.  
Both MTS and AK analysis of CB[7] revealed high cell viability and low cell 
death comparable to the untreated samples up to a concentration of 1 mM in HEK293 
(Figure 20A and B), HepG2 (Figure 20C and D) and RAW264.7 (Figure 20E and F) cell 
lines. Within the scope of this study, up to a concentration of 1 mM, these results indicate 
that CB[7] is non-toxic to these cell lines. Several studies have been conducted into the 
safety of CB[7]. Several toxicity studies have been conducted using CB[7] in many 
different cell lines including Chinese hamster ovary cells, human blood tissue, mouse 
embryo cells and the human cancer cells up to a concentration of 100 mM [146]. 
Furthermore, in vivo experiments in mice have shown no adverse effects up to a 
concentration of 200 mg/kg [141]. 
Future studies in toxicology include assessment of biotin-CB[7] both in vitro and 
in vivo. Taking the biocompatibility of its individual components, biotin[50] and CB[7], 
it can be hypothesized that biotin-CB[7] may be fairly non-toxic within the parameters 
established above. However, it is still necessary to evaluate the delivery system as a 
whole, in vivo, so that a safe dosing schedule may be established for this targeted 
molecule. Collected data should be compared to other targeted drug delivery systems to 
determine its significance. If good efficacy is established in vivo, it will be necessary to 
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do a full spectrum of safety analysis as suggested for Motor1. This compound has a very 
long way to go before it can be considered for an IND.  
 
7.2 Determination of the uptake and localization of CB[7] and biotin 
functionalized CB[7] 
7.2.1 CB[7] is taken up through phagocytosis by murine macrophages and localizes 
in lysosomes.  
The dose-dependent uptake of CB[7] was characterized via flow cytometry using 
3.2 and a 32 mM of CB[7]-FITC (Figure 21). CB[7]-FITC was incubated with 
RAW264.7 cells for 20 min before analysis. A dose of 3.2 and 32 mM resulted in median 
fluorescence intensity (MFI) of 197 and 703 while the untreated sample was at a value of 
131 (Figure 21A). Statistical analysis of the histograms showed the percentage of cells 
positive for CB[7]-FITC staining as an average of 5% for untreated cells, 24% for a 
concentration of 3.2 mM, and 86% for 32 mM (Figure 21C)[145].  
To determine the intracellular stability of the CB[7]-FITC complex a time course 
assay was conducted. CB[7]-FITC was incubated with the cells for 20 min and then 
chased for 15, 45, and 120 min. This resulted in high MFIs of 743 after 15 min chase, 612 
after 45 min, and 544 after 120 min chase time (Figure 21B). Further analysis determined 
that the percentage of cells positive for staining was 6% for untreated cells, 92% after 15 





Figure 21: CB[7]-FITC is taken up by murine macrophages in a dose dependent 
manner.  Both the dose titration and time course assays used RAW264.7cells incubated 
with CB[7]-FITC for 20 mins prior to analysis. (A) Dose titration assay used CB[7]-FITC 
concentrations of 3.2 (green) and 32 mM (red). (B) Statistical analysis of the percentage 
of cells positive for fluorescence. (C) Time course assay was conducted using 32 mM of 
CB[7]-FITC. After incubation with the fluorescent container, cells were chased for 15 
(green), 45 (red) and 120 min (blue) (D) Statistical analysis of the percentage of cells 
positive for fluorescence. Unpaired t-test analysis was used (*P=0.01–0.05; **P=0.001–





Co-localization assays using fluorescence microscopy were conducted using 
Dextran-647, and CB[7]-Alexa555 in order to analyze the intracellular localization of the 
container. Dextran-647 was incubated with cells at a concentration of 125 mg/mL 
overnight to stain cell lysosomes. Cells were then pulsed with CB[7]-Alexa555 for 20 
min and chased for 15, 45, 120 min. This analysis showed an initial uptake of CB[7]-
Alexa555 and Dextran-647 at 15 min with little colocalization (Figure 22A), however, at 
45 min, CB[7]-Alexa555 co-localization (indicated by arrows) with Dextran-647 was 
















Figure 22: CB[7]-FITC are taken up by murine macrophages through phagocytosis 
and localizes in lysosome.  Cell incubated with Dextran-647 (green) and CB[7]-FITC 
(red) showed intracellular localization of CB[7] through the endosomal pathway. 
RAW264.7cells were incubated with Dextran-647 (green) overnight and CB[7]-FITC 
(red) for 20 min the following day. Cells were chased for 15 (A), 45 (B) and 120 min (not 
shown) after incubation with CB[7]-FITC. Cells were imaged using confocal microscopy. 








7.2.2 Biotin-CB[7] binds to and is taken up through receptor-mediated endocytosis 
in murine lymphocytic leukemia cells.  
L1210 (Figure 23A; green) and L1210FR (Figure 23A; red and blue) cells were 
incubated with 2 µM of CB[7]-FITC (red) and biotin-CB[7]-FITC (green and blue) for 30 
mins. Binding was quantified using flow cytometry at a reading of 10,000 cells/condition. 
Results showed an MFI of 1449 for CB[7]-FITC incubated with L1210FR cells (red), 
1648 for biotin-CB[7]-FITC in L1210 cells (green), and finally an MFI of 5131 for 
biotin-CB[7]-FITC in L1210FR cells (blue).  
A biotin competition assay (Figure 23B) was conducted using L1210 and 
L1210FR cells incubated first with increasing concentrations of free biotin (0, 0.05, 0.5, 
5, 50 and 500 µM) for 30 mins followed by biotin-CB[7]-FITC (2 µM) for 30 mins. 
Quantification through flow cytometry indicated an average of 26.3%, 16.2%, 11.2%, 
10.6%, 10.5%, and 8.9% of the L1210 cell population to be biotin-CB[7]-FITC positive 
with 0, 0.05, 0.5, 5, 50 and 500 µM free biotin pre-treatment respectively. An average 
92.4%, 85.8%, 76.9%, 51.1%, 36.1%, and 27.3% of the L1210FR cell population was 
found to be biotin-CB[7]-FITC positive after 0, 0.05, 0.5, 5, 50 and 500 µM free biotin 








Figure 23: Biotin-CB[7]-FITC selectively binds to murine lymphocytic leukemia 
cells that overexpress the biotin receptor. L1210FR (red and blue) and L1210 (green) 
cells were incubated with 2 µM of CB[7]-FITC (red) and Biotin-CB[7]-FITC (green and 
blue) for 30 mins (A). Uptake was quantified with flow cytometry; 10,000 cells/sample 
were analyzed. This figure is representative of three experimental repeats. L1210FR and 
L1210 cells were incubated with increasing concentrations of  biotin (0.05-500 µM) for 
30 mins, washed, and then incubated with biotin-CB[7]-FITC  (2 µM) for 30 mins (B). 
Cells were then collected for quantification with flow cytometry; 10,000 cells/sample 
were analyzed. This figure is the average of two experimental repeats, and standard 
deviation was calculated at n = 4. Unpaired t-test analysis was used for statistical analysis 









Fluorescent microscopy conducted on L1210FR cells (Figure 24) showed high 
fluorescence in the FITC channel when incubated with biotin-CB[7]-FITC (green) for 30 
mins at 37
o
C. Colocalization (as indicated by arrows) of dextran-647 (red) and FITC 
(green) was also observed in these cells. This staining pattern was not observed in cells 
treated with CB[7]-FITC treated cells. A kinetics analysis of L1210FR cells treated with 
biotin-CB[7]-FITC (green) at 2 and 15 µM at 4
o
C for 1.5 hrs indicated peripheral staining 
of L1210FR cells (Figure 25). At 30 mins chase time, staining was observed throughout 












Figure 24: L1210FR cells incubated with 2 µM (A) and 15 µM (B) of Biotin-CB7-
FITC and CB7-FITC. indicated receptor specific uptake. Cells were treated with 
Dextran-647 (red) overnight followed by targeted and untargeted CB[7]-FITC (green) the 
next day. Colocalization (indicated by arrows) of dextran-647 with targeted CB[7]-FITC 
in the bright field overlay indicated internalization of Biotin-CB[7]-FITC (green) through 





Figure 25: L1210FR showed receptor specific uptake of Biotin-CB[7]-FITC.  
L1210FR were incubated with 15 µM of biotin-CB7-FITC (green) for 1.5 hrs at 4
o
C, 
washed, and chased for 0 (A and B) and 30 mins (C and D) at 37
o
C. Confocal imaging 
showed peripheral FITC staining (A) at 0 min chase time indicating biotin-CB7-FITC 
binding and immobilization on the cell surface. Internalization of biotin-CB[7]-FITC was 
observed at 30 min chase time (C). Fluorescence intensity was quantified across the 
indicated line for each image confirming surface staining (B) and internalization (D). 








 In order to elucidate if and where CB[7] would localize intracellularily, kinetics 
assays were conducted using Alexa-555 or FITC tagged CB[7] incubated with 
RAW264.7 cells. These cells were chosen because as macrophages, they have a high rate 
of endocytic and pinocytic activity thus maximizing the probability that the host 
molecules will be engulfed by the cells leading to intracellular localization (Figure 21 and 
22).  
The fluorescent CB[7] complexes used in these experiments were held together 
by non-covalent interactions through adamantaneamine linkages[145]. Accordingly, there 
is the possibility of an equilibrium between the free and bound dye forms. It is known, 
however, that CB[7] binds with adamantaneamine and its derivatives with extraordinarily 




) which ensures that these complexes are 
thermodynamically and kinetically stable at the concentrations and times used in these 
confocal microscopy and flow cytometry experiments[139, 145]. As a result it can be 
concluded that the fluorescent signals collected in both flow cytometry and confocal 
microscopy is representative of the CB[7]-tag complex.  
RAW264.7 cells incubated with 3.2 and 32 mM of CB[7]-FITC indicated dose 
dependent uptake by the cells as would be expected in these cells (Figure 21A and C). 
The kinetics assay showed increasing uptake of CB[7]-FITC with extended chase times 
indicating complex stability up to 120 mins (Figure 21B and D). These results were 
reflected in confocal microscopy studies conducted using CB[7]-FITC incubation 
followed by the same chase times: 15, 45, and 120 mins (Figure 22A, B and not shown 
respectively). In this study, dextran-647 (green) was used to label the endosomal pathway 
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prior to incubation with CB[7]-FITC (red). Co-localization (as indicated by arrows) for 
dextran-647 with CB[7]-FITC indicated that CB[7] is, in fact, take up through the 
endocytic pathway, and at 45 mins rests in lysosomes.  
Similar studies have been published analyzing the uptake of fluorescently tagged 
CB[7] by different cell lines. CB[7] binds tightly to acridine orange and this complex was 
previously used to demonstrate the uptake of CB[7] by mouse muscle embryo cells 
(NIH/3T3)[197]. In addition, a CB[6] loaded with a FITC-spermine conjugate was shown 
to be internalized by HepG2 cells[198]. Both of these studies, however, did not quantify 
the uptake of the container nor did they investigate its intracellular localization but 
nevertheless they demonstrated that other cell types besides macrophages are able to take 
up CB[n] containers.  
As a whole, these studies strongly suggest that untargeted CB[n]-type containers 
are able to cross into cells through the endocytic pathway and localize in the lysosomes 
of cells. This can be used for the controlled intracellular release of drugs under specific 
pH. CB[n] can be functionalized so that they release their guest molecules in the 
lysosomes at a pH of ~5. This, of course, requires that the released drug survive the harsh 
environment of the lysosomes.  
L1210FR and L1210 were used to determine whether the biotin functionalized 
CB[7] is selectively bound to and taken up by cells overexpressing the biotin receptor 
(Figure 23-25). L1210FR cell line was used specifically because they overexpress the 
biotin receptor on the cell surface like many tumor cells do while L1210 cells have 
normal biotin receptor expression as normal healthy cells would[194, 199]. L1210 and 





prior to analysis with flow cytometry (Figure 23A). Analysis showed similar MFI for 
CB[7]-FITC incubated with L1210FR (MFI = 1449) and biotin-CB[7]-FITC incubated 
with L1210 (MFI = 1648). This seems to indicate that there is little to no binding of 
untargeted CB[7]-FITC to cells overexpressing the biotin receptor and limited, though 
slightly higher, uptake of biotin-CB[7]-FITC to cells with normal biotin receptor 
expression. This slight increase in uptake should be excepted as the L1210 is not negative 
for the biotin receptor. There was, however, a significant increase in fluorescence 
intensity seen in the L1210FR cells treated with biotin-CB[7]-FITC (MFI = 5131). This 
seems to indicate that there is extensive binding of the biotin-CB[7]-FITC by the cells 
overexpressing biotin receptors (Figure 23A).  
Selective targeting of biotin-CB[7]-FITC to cells overexpressing the biotin 
receptors was further validated in the biotin competition assay conducted using these 
same conditions after treatment with increasing concentrations of free biotin (Figure 
23B). At high concentrations, free biotin binds to and occupies biotin receptors on the 
cell surface, thereby, limiting the binding of biotin-CB[7]-FITC through receptor 
saturation. This is indicated by the decrease in percent biotin-CB[7]-FITC positive cells 
following pretreatment with high concentrations of free biotin (at 0, 0.05, 0.5, 5, 50, 500 
µM of free biotin, there is 92.4, 85.8, 76.9, 51.1, 36.1, and 27.3% biotin-CB[7]-FITC 
positive cells respectively). This phenomenon was not reflected in L1210 treated the 
same way. No significant increase or decrease in percent biotin-CB[7]-FITC positive 
cells was observed at any concentration of free biotin in this cell line. There results seem 
to indicate that there was no significant binding of biotin-CB[7]-FITC to the biotin 
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receptors on L1210, while there was significant binding of biotin-CB[7]-FITC to the 
L1210FR which overexpress the biotin receptor. 
Selective receptor binding was visualized and quantified using confocal 
microscopy and flow cytometry. The first experiment involved continuous L1210FR 
incubation with CB[7]-FITC and biotin-CB[7]-FITC at 2 (Figure 24A) and 15 µM 
(Figure 24B) for 30 mins at 37
o
C. A clear and significant increase in fluorescence was 
observed in the FITC channel (green) at both concentrations (Figure 24) of biotin-CB[7]-
FITC while no significant fluorescence was observed in the cells incubated with CB[7]-
FITC. This significant difference in FITC staining suggests that biotin-CB[7]-FITC is 
binding to the overexpressed biotin receptors found on the surface of L1210FR cells 
while CB[7]-FITC is not. Because this experiment used confocal microscopy, this image 
is representative of a z-section of the middle of the cells which seems to show 
internalization of the biotin-CB[7]-FITC. Furthermore, colocalization (as indicated by 
arrows) of Dextran-647 (red) with biotin-CB[7]-FITC (green) treatment also seems to 
indicate internalization and localization in lysosomes of the biotin-CB[7]-FITC rather 
than simple surface staining. 
A kinetics assay was conducted using these same treatments. L1210FR cells were 
incubated at 4
o
C for 1.5 hrs with biotin-CB[7]-FITC at 2 and 15 µM (Figure 25A and B). 
This allowed for the biotin-CB[7]-FITC to bind to the biotin receptors on the cell surface 
while the endosomal pathways had been temporarily halted. Following incubation at 4
o
C, 
cells were thoroughly washed to remove any unbound compounds. Cells were then 
chased for 0, 15 and 30 mins with fresh media to restart the endosomal pathway. This 
would allow for the receptor mediated internalization any receptor bound compounds. 
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This study revealed peripheral punctured staining of the cells at 0 mins chase time 
(Figure 25A) suggesting that biotin-CB[7]-FITC is bound to biotin receptors on the cell 
surface. At 30 min chase (Figure 25B), a hazy, all around staining was observed 
indicating internalization of the targeted delivery system. This experiment further 
confirmed that biotin-CB[7]-FITC is, in fact, being internalized through selective 
receptor mediated endocytosis. One drawback of these two experiments is the difficulty 
with which it is to see the cytosolic or lysosomal staining sometime. This is most likely 
due to the fact that these cells are non-adherent and, therefore, rounded with limited 
visible cytosols. These binding an uptake experiments seem to lend towards the 
hypothesis that biotin-CB[7] can be targeted to and selectively taken up by cells 
overexpressing the biotin receptor (like many tumor cells) while being excluded by 
healthy cell with normal biotin receptor expression.  This suggests that this system can be 
used to specifically delivery anti-cancer drugs to tumors while leaving healthy cells alive.  
It should be noted here that the heterogynous staining observed in Figure 25 could 
be due to different factors. One such explanation could be that these non-adherent cells 
were in a clump during the staining process thus limiting the biotin-CB[7]-FITC and 
dextran-647 access to cells in the middle of the clump. It may also be possible that 
because these are non-adherent cells, they are on different planes on the z-axis thus 
limiting the visibility of the staining. Finally, it may also be possible that the unstained 
cells are unhealthy and, therefore, have limited receptor-mediated uptake either during 
the time of staining. There are several ways to improve these confocal microscopy 
studies. One way would be to decrease the number of cells used in the experiment while 
increasing the amount of agitation during the staining process so as to minimize 
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clumping. Finally, to further support the idea that biotin-CB[7]-FITC is, in fact, 
internalized, this experiment could be repeated with an extracellular quenching agent to 
eliminate extracellular fluorescence or to present the images using full z-stack, 3D image 
of the cells.  
A primary future study would be to evaluate whether the selective binding and 
uptake of biotin-CB[7] can be translated in vivo. There are many problems that arise 
when translating ligand targeted therapeutics into the animal model. This is a primary 
reason why there are limited compounds currently in advanced stages of development. 
One important obstacle is the rapid clearance of targeted DDSs. In fact, many studies 
have shown that the pharmacokinetics and biodistribution of ligand targeted particles do 
not usually differ significantly from free drug due rapid clearance from the body[200]. 
Furthermore, if a targeted DDS is too small to induce the EPR effect, it may likely be 
filtered out of the tumors fairly quickly, giving the targeting ligands limited time to bind 
to receptors on tumor cells [200]. These particles will then be back in general circulation 
and be cleared from the system through renal filtration. This rapid filtration and systemic 
clearance could limit cell uptake of the drug and render the therapy ineffective. 
Therefore, it is clear that ligand targeted delivery of drugs may not be enough.  
PEGylation of a DDS could both extend circulation time and promote retention of 
DDSs by inducing the EPR effect[95], however, PEGylation alone is also not enough to 
produce an effective targeted DDS. There are several reasons for this. For the EPR effect 
to be efficient, the DDS must remain in circulation at high concentrations for more than 6 
hrs[100, 201]. Furthermore, the EPR effect only allows for the accumulation of the drug 
in the tumor tissue, and does not imply that the drug is actually released from the 
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nanoparticle or that the drug or DDS is taken up by the tumor cells[199]. This uptake can, 
however, be guaranteed by using a targeting ligand like biotin.  
Therefore, it may be prudent to include a targeting ligand in addition to 
PEGylating a delivery system as it is clear that both methods of targeting may be 
necessary for effective delivery[200]. This system would theoretically 1) reach the tumor 
successfully with limited to no phagocytosis and inactivation by macrophages and blood 
proteins, 2) accumulate within the tissue as a result of the EPR effect, 3) bind to tumor 
specific receptors through their targeting ligands thus retaining the drugs in the tumor and 
4) allow for the DDS to be taken up into the cell through receptor mediated endocytosis.  
There are several targeted delivery systems that are currently in clinical trials that 
utilize both these components to enhance drug delivery. One such example is BIND-014 
which is a PSMA aptamer targeted PEG/PLGA nanoparticle loaded with the anticancer 
docetaxel[188].  
 
7.3 In vitro evaluation of drug efficacy upon loading into targeted and untargeted 
CB[7].   
7.3.1 Ethambutol (EMB) retains its efficacy upon coupling with CB[7]  
RAW264.7 cells were infected with M. smegmatis and then treated with EMB and 
CB[7]-EMB for 3 days after which time the amount of viable bacteria was determined 
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respectively. The values of CFUs within each MIC dose for free EMB or CB[7]-EMB 















Figure 26: M. smegmatis treatment using the TB drug EMB loaded into CB[7] 
(CB[7]-EMB, white bars) were equally effective in treating M. smegmatis infected 
RAW264.7 cells as free EMB (patterned bars). RAW264.7cells were incubated with 
M. smegmatis for two hours and then chased for three days with EMB and CB[7]-EMB. 
Varying MIC values for EMB and CB[7]-EMB were used: 0.1, 0.4, 0.8, and 1 units. 
Viable bacteria were quantified using CFU/ml. This figure is representative of two 
replicate experiments, unpaired student t-test was conducted. Work was done by Gaya 










7.3.2 Increased oxaliplatin efficacy is observed as a result of increased drug uptake 
due to targeted delivery by biotin-CB[7].  
 In this study, oxaliplatin was loaded into untargeted CB[7] (CB[7]-Oxaliplatin), 
and targeted biotin-CB[7] (biotin-CB[7]-oxaliplatin) (Figure 27). These compounds were 
used to treat L1210FR and L1210 cells along with the oxaliplatin alone at increasing 
concentrations (0, 0.5, 5, 15, 25, 50, 150 and 250 µM) (Figure 27A). MTS analysis 
revealed that L1210FR treated with oxaliplatin resulted in an average of 100%, 95%, 
107%, 106%, 106%, 83%, 59%, and 59% cell viability respectively. CB[7]-oxaliplatin 
resulted in an average of 100%, 108%, 125%, 110%, 96%, 83%, 60% and 57% cell 
viability and an average of 100%, 107%, 96%, 55%, 60%, 36%, 48%, and 44% cell 
viability was observed with increasing concentrations of biotin-CB[7]-Oxaliplatin.  
In the L1210 cell line, the same concentrations of oxaliplatin resulted in 100%, 
87%, 93%, 90%, 94%, 93%, 51%, and 49% cell viability. CB[7]-oxaliplatin resulted in 
100%, 102%, 104%, 111%, 100%, 111%, 74%, and 52% cell viability while biotin-
CB[7]-oxaliplatin resulted in 100%, 89%, 89%, 78%, 65%, 55%, 38%, and 34% cell 












Figure 27: Biotin-CB[7]-Oxaliplatin results in target specific decrease in cell 
viability in the biotin receptor positive murine lymphocytic leukemia cell line 
(L1210FR). L1210(B) and L1210FR (A) cells were incubated with Oxaliplatin (black 
circle), CB[7]-Oxaliplatin (open circle),  and Biotin-CB[7]-Oxaliplatin (black square) for 
45 mins. Cells were then washed and incubated in fresh media for 24 hrs prior to analysis 
with the MTS assay.  These figures are representative of three experimental repeats (n = 
3) (A) and two experimental repeats (n=4) (B). The unpaired student t-test was 




 7.3.3 Discussion 
In order to assess whether CB[7] binding would inhibit the activity of an 
encapsulated drug, EMB loaded CB[7] was used to treat M. smegmatis infected 
RAW264.7 cells (Figure 26). EMB was specifically chosen because it is a widely used 
anti-tuberculosis drug with high efficacy and minimum side effects. Therefore, any 
inhibition of the drug’s activity by CB[7] would be readily observable upon treatment. M. 
smegmatis is a non-virulent mycobacterium often used as a model for tuberculosis 
infections[202] and is treatable with EMB. Treatment of infected RAW264.7 cells with 
free EMB and CB[7]-EMB revealed equal and efficient killing of bacteria by both with 
increasing doses of the drug. No significant difference in efficacy was found between the 
free and encapsulated drug, therefore, suggesting that CB[7] does not inhibit the activity 
of EMB. It has been shown previously, that CB[7] loaded with the anticancer drug 
oxaliplatin reduced the activity of the drug by 5–10 fold depending on the specific cancer 
cell line used for treatment[146]. In contrast, no to moderate decrease of activity upon 
loading into CB[7] has been reported for a dinuclear platinum complex[203]. The latter 
finding could be confirmed in an in vivo cancer model using Balb/c mice bearing human 
ovarian cancer[196]. Thus it seems that potential inhibitory effects of loading drugs into 
CB[7] have to be determined for each individual drug. This experiment also further 
perpetuates the idea that CB[n]-type molecular compounds can be used across therapeutic 
fields and not just in the field of cancer.  
Next we attempted to elucidate whether a biologically active anti-cancer drug 
could be delivered specifically to tumor cells overexpressing the biotin receptor and, as a 
result, cause specific cell death.  For this purpose, a biotin-CB[7]-oxaliplatin complex 
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was used in the treatment of L1210 and L1210FR cells (Figure 27). Oxaliplatin is a very 
potent and efficacious drug with problems with severe toxicity and would, therefore, 
benefit from the targeted drug delivery system. Cell viability results using this system 
indicate a significant decrease in cell viability (55 and 47% cell viability) in L1210FR 
cells at only 15 µM of biotin-CB[7]-oxaliplatin. However, treatment with the oxaliplatin 
or CB[7]-oxaliplatin alone in these cells did not result in a significant decrease in cell 
viability until a concentration of 150 and 50 µM which resulted in 59 and 60% cell 
viability respectively (Figure 27A). In contrast, no significant differences was detected 
between targeted and untargeted CB[7]-oxaliplatin in the treatment of L1210 cells where 
a decrease in cell viability was not detected until a concentration of 50 µM (Figure 27B). 
These results suggests that oxaliplatin loaded into biotin-CB[7] allows for the specific 
binding to and cytotoxicity in cells overexpressing the biotin receptor while leaving cells 
with normal receptor expression healthy. Furthermore, this study suggests the need for 
lower drug concentrations to induce greater cytotoxicity in L1210FR cells when 
oxaliplatin is delivered using the biotin-CB[7] system.  Both these factors combined can 
lead to significantly diminished side effects in chemotherapy. Finally, cell death results 
suggests that oxaliplatin is, in fact, internalized and released from the delivery system so 
that it can bind to DNA and induce cell death through its mechanism of action.  
The significant differences in cell death between oxaliplatin, and CB[7] 
encapsulated drug systems in the L1210 cell line could be attributed to the fact that CB[7] 
may be limiting oxaliplatin bioactivity (Figure 27B). This phenomenon was demonstrated 
by the Kim group [146] in a variety of different cell lines in vitro stating that this could 
be due to inadequate uptake of CB[7]-oxaliplatin. It is important to note here though, that 
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this behavior is not reflected in the L1210FR cell line upon treatment with biotin-CB[7]-
oxaliplatin thus further validating the receptor specific uptake of the targeted DDS and 
eventual release of the drug with the cell. This also seems to suggest that limited harm 
can be done to “healthy” cells with untargeted or targeted CB[7]-oxaliplatin while free 
oxaliplatin results in high cell death. This again validates the need to use a targeted drug 
delivery system like biotin-CB[7] to delivery oxaliplatin.  
An essential future study to evaluate the plausibility of a targeted CB[n] is to 
translate this system in vivo as mentioned previously. As previously stated, these biotin-
CB[7]-oxaliplatin particles could be cleared from the blood quickly with limited access to 
the tumor, however, there are other considerations in the practical use of this compound 
and the CB[n]s as targeting molecules to also consider. One factor is that DDSs like 
liposomes and dendrimers are able to carry and delivery large numbers of drug 
molecules/nanoparticle[108, 111, 193], however, the CB[7] is limited to one drug 
molecule/CB[7] at best. One way researchers have somewhat circumvented this problem 
in CDs is by using CD-polymer nanoparticles that allow for the loading of more than one 
drug particle at a time. An example of this is CRLX101 which is a PEG-CD based 
nanoparticle that can bind to and protect CPT[163]. In clinical trials, this compound has 
demonstrated improved pharmacokinetics and efficient protection and passive targeting 
of active CPT to tumors. Nanoparticles with repeating CB[n] units have been constructed 
before, however, an ideal chemical balance in necessary to properly encapsulate and 
actually delivery drug particles effectively in vivo[204]. 
Another problem that is prominent with targeted drug delivery is drug leakage. 
For a targeted DDS to be effective, the drug must be maintained, at its original 
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concentration, within the delivery system until it reaches the tumor. However, the 
problem with many targeted DDSs is the leakage of drug from the DDS leading to high 
levels of toxicity and ineffective treatment. This is a more prominent problem with the 
CB[n] family, because like the CDs, these macromolecules are at an equilibrium between 
bound and unbound drug. As explained before, this means that any changes to this 
equilibrium, like high dilutions upon i.v. administration, would release the drug from the 
CB[n]. This could render any targeted CB[n] ineffective and would lead to high toxicity. 
PEGylating a compound has been demonstrated to provide some added encapsulation 
time of drugs within liposomes, but it may not be the ideal solution for CB[n]s. One 
possible solution might be to use Motor2 as a targeted delivery system. As stated before 
Motor2 binds to certain drugs, like CPT, with very high binding affinity and may retain 
the drug until the system reaches the tumor. It should also be noted that Motor2’s ability 
to tightly bind drug compounds may also lead to problems with releasing the drug when 
it does reach the tumor. A second solution to this problem may be to construct a prodrug 
system that would result in the controlled and specific release of the drug at the tumor 
vasculature or within tumor cells. One stimulus that could trigger the cleavage of a 
prodrug and the release of the active drug would be the low pH of tumor vasculature.  
One such targeted DDS that uses passive and active targeting in addition to a 
prodrug system is synthesized and extensively tested in Dr. Farokhad’s lab (Harvard 
Medical School, Boston, MA)[74]. This compound is a PLGA-b-PEG, PSMA aptamer 
targeted nanoparticle that has a prodrug formulation of a potent platinum (Pt) based 
anticancer drug. Preclinical studies established the MTD values of this compound in rats 
was established at twice the dose of Pt alone (40 mg/kg vs. 20 mg/kg) and this targeted 
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compound was found to have significantly extended systemic circulation time, decreased 
accumulation in the kidney (less toxicity), and only about a third of the drug was need to 
elicit the same response as cisplatin delivered through conventional methods.  
Furthermore, the prodrug holds the drug in within the nanoparticle in an inactive form.  
Due to these proposed limitations and those mentioned in the previous discussion 
section, it is clear that targeted CB[n] and CB[n]-type compounds have a long way to go 
before reaching the FDA approval process. Extensive formulation and in vivo studies will 
need to be done in close collaboration with Dr. Isaacs’ lab in order to design the ideal 
targeting molecule using the cucurbit[n]uril family of macromolecules. As part of this 
developing project, different CB[n]-type molecules with the ability to significantly 
increase the solubility of drugs, such as with Motor2, should be tested as alternative 
carriers for targeting. And finally, new targeting ligands like folate, anti-PSMA particles, 













Chapter 8. THESIS CONCLUSION and FUTURE IMPLICATIONS  
The wellbeing of the public greatly depends on the discovery and development of 
novel drugs, however, the productivity of the drug development pipeline has significantly 
decreased over the past few years. In fact, for every 10,000 drug candidates that enter the 
drug development pipeline, only one is eventually approved by the FDA and marketed in 
addition to significantly rising costs/drug[10, 12]. This decline in productivity within the 
development pipeline is referred to as drug development attrition. The highest 
contributors to developmental attrition are high drug toxicity (11% of all failed drugs), 
low efficacy (30%) and low drug bioavailability (39%)[12].  
One solution to alleviate attrition rates is to use excipients and DDSs to improve 
drug bioavailability by enhancing drug solubility or improve drug toxicity through the 
targeted drug delivery[63, 80, 82, 98]. There are many different kinds of excipients and 
DDSs currently being studied and marketed including polymers, liposomes and CDs[92, 
122, 180]. A new family of macromolecules proposed for these uses is the CB[n] 
family[138]. Despite the fact that there are so many different kinds of successful 
excipients and DDSs both under research and being marketed, there is a continuous need 
to expand this toolbox. The reason for this is that no one host molecule can solubilize and 
help deliver every drug compound.  
As a result, here, we have introduced and evaluated three new CB[n]-type 
molecules. Motor1, Motor2 and functionalized CB[7] were synthesized and their 
chemical properties analyzed in Dr. Lyle Isaacs’ lab. Their work demonstrated that 
Motor1 and 2 can increase the solubility of a large variety of drugs across therapeutic 
fields, many of which HP-β-CD could not (Table1). Some of the most striking were PBS-
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1086 (7.5 mM increase with Motor1), PTX (~2750 fold increase with Motor1), 
melphalan (~1690-fold increase with Motor1 and 2), CPT (~580-fold with Motor2), and 
cinnarizine (~308-fold increase with Motor1). There are many drugs, currently being 
investigated, abandoned or marketed, that cannot be formulated with other excipients 
without inducing high toxicity but it may be improved by using Motor1. The re-
formulation and approval of these drugs can have an immense impact on improving 
public health by increasing the diversity and availability of drugs in the market, not just 
in the field of cancer, but across therapeutic fields. Of course there are several 
compounds that are not compatible with Motor1 or 2, like the anticancer drug 
doxorubicin, therefore, here we do not necessarily strive to replace established excipients 
like CDs and liposomes.  Instead we hope to add to the expanding toolbox currently 
available and provide a wider range of alternatives for solubilizing drugs. 
In vitro and in vivo analysis of Motor1 suggested that it was highly biocompatible 
and is able to solubilize a large variety of drugs without inhibiting drug activity. Some of 
the most pressing studies that will need to be conducted with this compound in the near 
future include adequate in vivo evaluation of Motor1-drug complexes. This not only 
entails further evaluation of Motor1-drug efficacy, but also Motor1-drug 
pharmacokinetics to clearly establish the bioavailability, biodistribution and clearance of 
these compounds.  The information collected from studies conducted in rodent models 
(like rats) will provide a clear idea of how useful Motor1 will be in the clinical setting 
and will also allow for us to establish adequate dosage and dosing schedules for 
translation into non-rodent models.  Following the outcome of these in vivo experiments, 
further development of Motor1 can be pursued by conducting a more in-depth analysis of 
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Motor1 toxicity in accordance with requirements and guidelines set forth by the FDA 
such as evaluating genetic toxicity, immunotoxicity, reproductive/developmental etc. It is 
essential to establish these in rodent and non-rodent models. The most immediate and 
relevant toxicity study may be in vitro genetic toxicity testing and evaluating in vivo 
immunotoxicity as detailed in the discussion of Motor1 biocompatibility. Furthermore, it 
may be essential to begin to establish the long-term repeat dose effects of Motor1. An 
MTD study of Motor1 and 2 in rats is already underway in a collaboration with Dr. 
Matthias Eikermann (Massachusetts General Hospital, Harvard Medical School, Boston, 
MA). Another avenue that may be interesting to explore further down the road, once 
essential parameters have been established, is to investigate whether Motor1 can be used 
for the oral administration of drugs. Additionally, other fields of therapy should also be 
explored given Motor1’s ability to increase the solubility of drugs across therapeutic 
fields (Table1). Both of these investigations would significantly expand the therapeutic 
reach of this delivery system and increase the impact Motor1 has on public health. 
Finally, biologically evaluation of Motor2 should commence in the near future to 
establish its potential use as a drug delivery system.  
Dr. Isaacs’ lab was also able to successfully ligate biotin to the surface of CB[7] 
in order to create a delivery system that could deliver drugs specifically to tumors that 
overexpress the biotin receptor on the cell surfaces. This kind of targeted drug delivery 
system would help alleviate severe side effects associated with cancer therapy. This 
system was shown to be effective in in vitro treatment against cell lines overexpressing 
the biotin receptor, however, the practical translation of this system into the in vivo model 
and then into humans will need extensive thought and research as detailed in the 
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discussion sections. There are several disadvantages to this system that may need to be 
improved upon before further study can be conducted into targeted tumor treatment. One 
disadvantage is that, because of its small size, it may be cleared for tumor vasculature 
very quickly thus limiting the time biotin-CB[7] has to bind to its receptors on cancer 
cells. Furthermore it can also be cleared from systemic circulation very quickly, thus 
limiting its bioavailability. One possible option towards improving circulation and 
retention time is to PEGylate the targeted compound. It may also be possible to form 
nanoparticles from targeted CB[n] and PEG like with CRLX101. This is a CD-PEG 
based nanoparticle that can delivery active CPT to tumors very effectively. It is currently 
in clinical trials[162]. A nanoparticle such as this also demonstrates the added advantage 
of being able to delivery multiple drug molecules in one nanoparticle. However, the 
restructuring of biotin-CB[7] and plausibility of these solutions will have to be carefully 
evaluated by Dr. Isaacs.  
A second disadvantage to biotin-CB[7] is the fact that the CB[n]-drug system 
works on an equilibrium between bound and unbound drug much like the CD family. 
This system takes advantage of factors, like high dilutions, that can shift this equilibrium 
to release and retain free drug from the CB[n]. When targeting a drug molecule to a 
tumor, the drug must be maintained within the carrier until it reaches and binds to the 
tumor; with the current biotin-CB[n] system, this is not the case. Theoretically, when the 
biotin-CB[7]-drug compound reaches a high dilution in the blood upon i.v dosing, the 
drug will be released before the system reaches the tumor. One potential solution to this 
may be to explore Motor2 as a targeted DDS due to its high affinity towards drug 
compounds like CPT. However, drug release will have to be closely monitored to ensure 
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drug efficacy is maintained. A second option would be design a prodrug system that 
would allow for the retention and controlled release of the drug specifically at the tumor. 
One example that uses all three elements of an ideal targeted drug delivery system is the 
PSMA aptamer targeted PLGA-b-PEG nanoparticle encapsulating the Pt (IV) prodrug 
that was discussed previously[74].  
In an effort to understand what would happen to the biotin-CB[7] in vivo it may 
be conducive to quantify and visualize the biodistribution of biotin-CB[7] through live 
animal imaging. This would give practical information about whether tumor targeting 
with this compound is plausible and what problems we can expect to run into with 
targeted in vivo drug delivery.  If encouraging results are collected, in vivo treatment of 
biotin overexpressing tumors can be conducted to evaluate whether a drug can be 
delivered to tumors while maintaining efficacy. Following these studies, further 
investigation into the pharmacokinetics and safety profile of this targeted compound can 
be conducted in a similar manner to that of Motor1. 
Despite their limitations and the need for further investigation, the results 
presented in this thesis provide an encouraging proof-of-principle towards the use of 
CB[n]-type compounds for enhancing the solubility and targeting the delivery of many 
drugs. By improving drug solubility and toxicity profiles, these compounds may be able 
to help get essential therapies marketed and as a result help reduce attrition rates within 
the drug development pipeline. These CB[n]-type compounds may be able to help 
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